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Abstract 
Adenosine-triphosphate-(ATP)-binding cassette (ABC) transport proteins are ubiquitously present membrane-
bound efflux pumps that distribute endo- and xenobiotics across intra- and intercellular barriers. Discovered over 
40 years ago, ABC transporters have been identified as key players in various human diseases, such as multidrug-
resistant cancer and atherosclerosis, but also neurodegenerative diseases, such as Alzheimer’s disease (AD). 
Most prominent and well-studied are ABCB1, ABCC1, and ABCG2, not only due to their contribution to the 
multidrug resistance (MDR) phenotype in cancer, but also due to their contribution to AD. However, our 
understanding of other ABC transporters is limited, and most of the 49 human ABC transporters have been largely 
neglected as potential targets for novel small-molecule drugs. This is especially true for the ABCA subfamily, 
which contains several members known to play a role in AD initiation and progression. This review provides up-
to-date information on the proposed functional background and pathological role of ABCA transporters in AD. 
We also provide an overview of small-molecules shown to interact with ABCA transporters as well as potential 
in silico, in vitro, and in vivo methodologies to gain novel templates for the development of innovative ABC 
transporter-targeting diagnostics and therapeutics. 
 
Keywords: ABC transporter, ABCB1 (P-gp), ABCC1 (MRP1), ABCG2 (BCRP), ABCA1 (ABC1), ABCA2, ABCA5, ABCA7, 
Multitarget inhibitor (PANABC), Broad-spectrum modulator, Alzheimer’s disease, Amyloid-beta (Aβ / Abeta), Inhibition, Activation, 
Induction, Downregulation, PET Tracer (PETABC), Pattern analysis, Polypharmacology, Rational drug design and development 
Review 
Free Neuropathology 2:33 (2021) Pahnke et al. 






From MDR to neurodegeneration: ABC transporters in human disease 3 
ABC transporters, Aβ proteins, and AD 5 
PART I: STATUS QUO 5 











Modulators of ABCA transporter function, trafficking, and regulation 10 
Small-molecule interactors of ABCA transporters 13 
Small-molecule regulators of ABCA transporters 22 
PART II: PIPELINE DEVELOPMENT TO GAIN NOVEL DIAGNOSTICS AND THERAPEUTICS 34 
In silico methodologies to predict novel lead structures 34 
Structure-based drug design 34 
Ligand-based drug design 36 
In vitro methodologies to assess novel lead structures 37 
Host system of ABCA transporters 37 
Functional assessment of ABCA transporters 38 
In vivo assessment of clinical candidates 43 
Knock-out mouse models 43 
RNAi models 44 
Overexpression models 44 
Humanized ABC transporter mouse models 45 
Disease models 45 
Imaging techniques 45 
CONCLUDING REMARKS: WHERE DO WE GO FROM HERE? 45 
APPENDIX 47 
Free Neuropathology 2:33 (2021) Pahnke et al. 





5-FU - 5-fluorouracil, Aβ - amyloid-β, ABCA - 
ATP-binding cassette transporter subfamily A,  
ACAT - acyl coenzyme A cholesteryl acyl transferase, 
AD - Alzheimer’s disease, ADMA - asymmetric 
dimethylarginine, ADP - adenosine-diphosphate, 
ALS - amyotrophic lateral sclerosis, AMPK - cAMP-
activated protein kinase, APOA1/E3/E4 - 
apolipoprotein A1/E3/E4, APP - amyloid precursor 
protein, ATP - adenosine-triphosphate, BBB - blood-
brain barrier, BCSFB - blood-cerebrospinal fluid 
barrier, BHK - baby hamster kidney, BIG1 - brefeldin 
1-inhibited guanine nucleotide exchange protein, 
BODIPY - 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene, cAMP - cyclic adenosine monophosphate, 
CFTR - cystic fibrosis transmembrane conductance 
regulator, CHO - Chinese hamster ovary, CNS - 
central nervous system, CPT-cAMP - 8-(4-
chlorophenylthio)-cAMP, Cryo-EM - cryogenic 
electron microscopy, CSF - cer-ebral spinal fluid, 
DIDS - 4,4’-Diisothiocyano-2,2’-stilbenedisulfonic 
acid, EC50 - half-maximal effect concentration,  
ECD - extracellular domain, ECGC - epigallocatechin 
gallate, ED50 - half-maximal effective dose, EOAD - 
early-onset AD, FPD5 - fluorescigenic pyrazoline 
derivative 5, FXR - farnesoid-X-receptor, GFP - green 
fluorescent protein, GGPP - geranylgeraniol 
pyrophosphate, GSH - reduced glutathione, GWAS - 
genome-wide association study, HD - Huntington’s 
disease, HDAC2 - histone deacetylase 2, HDL - high-
density lipoprotein, HMG-CoA-reductase - 3-
hydroxyl-3-methyl glutaryl-coenzyme A reductase, 
HTS - high-throughput screening, IC50 - half-maximal 
inhibition concentration, LAMP1 - lysosomal-
associated membrane protein 1, LDLR - LDR 
receptor, lncRNA - long non-coding RNA,  
LOAD - late-onset AD, LTC4 - leukotriene C4, LXR - 
liver-X-receptor, MDR - multidrug resistance,  
mRNA - messenger RNA, MS - multiple sclerosis, 
MSD - membrane-spanning domain, NBD - 7-nitro-
2,1,3-benzooxadiazole or nucleotide binding 
domain, NDEA - N-nitrosodiethylamine, NEM - N-
ethylmaleimide, (ox)LDL - (oxidized) low density 
lipoprotein, PCB29-pQ - 2,3,5-trichloro-6-phenyl-
[1,4]-benzoquinone, PD - Parkinson’s disease, PDB - 
protein data bank, PG-J2 - prostaglandin J2, PMA - 
phorbol 12-myristate 13-acetate, PPAR - 
peroxisome proliferator-activated receptor,  
PRDX1 - peroxiredoxin 1, RAR - retinoic acid 
receptor, RNA - ribonucleic acid, RXR - retinoid-X-
receptor, SAR - structure-activity relationships, 
shRNA - short-hairpin RNA, siRNA - small interfering 
RNA, SNP - single nucleotide polymorphism, SR-BI 
(Srb1) - scavenger receptor B1 (also HDL receptor), 
SREPB - sterol regulation element-binding protein, 
TKI - tyrosine kinase inhibitor, TKI - tyrosine kinase 
inhibitor, TM - transmembrane helix 
INTRODUCTION 
From MDR to neurodegeneration: ABC 
transporters in human disease 
ABC transporters are membrane-bound 
transport proteins that are ubiquitously present in 
the human body.1-4 They play a major role in 
determining the distribution of intrinsic and 
xenobiotic drugs between intra- and intercellular 
compartments.5,6 The clinical relevance of ABC 
transporters became pronounced when their 
expression was correlated to cross-resistance of 
cancer cells to antineoplastic agents.3,7-13 This 
phenomenon is called ‘multidrug resistance’ (MDR). 
However, despite enormous efforts and countless 
clinical trials to target these efflux pumps,14-17 MDR 
is still a major unresolved obstacle in cancer 
chemotherapy. To date, most ABC transporters have 
been associated with MDR,3,7-9,11,12 but only a small 
minority has been studied properly and can be 
addressed by small-molecule modulators.18-22 
Amongst these are ABCB1,1,18-27 ABCC1,1,18,19,23,24,26,27 
and ABCG2.18,19,25 
Apart from their role in multidrug-resistant 
cancer, many ABC transporters have been identified 
as key players in neurological disorders. Evidence for 
this includes their high abundance at the blood-
brain barrier (BBB) and blood-cerebrospinal fluid 
barrier (BCSFB) in the central nervous system 
(CNS).28-32 Additionally, their expression is altered in 
many pathological conditions in the brain.28-30,33-40 
Important players are, again, ABCB1,28-30,34-36,39-44 
ABCC1,28-30,39,41,43,45 and ABCG228,30,34,36,39-41,43 
in diseases like AD,28-30,41 amyotrophic lateral 
sclerosis (ALS),34,36,44 encephalopathy,45,46 
epilepsy,39,40 multiple sclerosis (MS),35 and 
Parkinson’s disease (PD).42,47   
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Table 1. ABC transporters and related neurological and psychiatric diseases. 
  




abnormal sphingolipid metabolism53,54 






ABCA13 Lewy body disease64 
psychiatric disorders48,65,66 
stroke in mice67 
ABCB1 AD28 
brain tumors68 





multiple systems atrophy73 
PD74 








ischemic stroke80  
ABCC2 brain tumors79 
epilepsy39 




limbic-predominant age-related TDP-43 encephalopathy (LATE)82 
hippocampal sclerosis of aging and depression83 
ABCD1 cerebral adrenoleukodystrophy84 
ABCG1 AD85 







traumatic brain injury92 
ABCG4 AD93 
HD51 
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Furthermore, ABC transporters were also found to 
be associated with certain genetic neurological and 
psychiatric diseases such as Huntington’s disease 
(HD),38 bipolar disorder,48,49 depression,48 or 
schizophrenia.48,49 Table 1 summarizes the 
involvement of ABC transporters in neurological 
diseases. 
ABC transporters, Aβ proteins, and AD 
Since 2001, ABC transporters have been implicated 
in AD pathogenesis.28-30,41,43,94,95 Specifically ABCB1,94 
ABCC1,96 and ABCG297 have been suggested to 
directly transport amyloid-β (Aβ) proteins, being 
involved in Aβ clearance from the brain to the blood 
stream.94,96,97 In light of the failure of the first 
immunological treatment studies,98 it was already 
proposed that ABC transporter dysfunction could 
explain the clearance problem of Aβ.99,100 Cerebral 
accumulation of Aβ proteins interferes with 
neuronal metabolite homeostasis and leads to 
interruption of cortico-cortical circuits and 
hampered synaptic communication. This results in 
an irreversible atrophy and degeneration of specific 
brain regions, which further causes behavioral, 
cognitive, and visuospatial impairments in the 
progression of AD.101  
The most prominent ABC transporter subfamily 
involved in AD is the ABCA subfamily of cholesterol 
and phospholipid transporters, in which particularly 
ABCA1, ABCA2, ABCA5, and ABCA7 have been 
associated with AD.28-30,41,43,95,102 For ABCA1,28,41,95,103 
and specifically for ABCA7,28,41,95,104-107 genetic 
variant28,41,108-111 and genome-wide association 
studies (GWAS)28,41,106,107,112 have suggested that 
these transporters are risk factors in AD. These 
discoveries give the members of the ABCA subfamily 
a special standing within the group of AD-related 
ABC transporters. 
Cholesterol metabolism in the context 
of AD has been discussed extensively 
before.95,102,104,105,113-116 The contribution of 
cholesterol and phosphilipid transport to membrane 
constitution, composition, fluidity, and lipid raft 
formation mediated by ABCA transporters has 
already been proposed,6 presenting a putative 
pharmacological target.117 Targeting cholesterol and 
lipid distribution impacts Aβ production by 
differential activities between α-, β-, and γ-
secretases, but also amyloid precursor protein (APP) 
processing106,118-122 and Aβ degradation.106,119,123-126 A 
contribution of ABCA transporters to Aβ clearance 
from the brain was also proposed,103,106,119,124,127 but 
not through direct Aβ transport.128,129 
Although ABCA transporters have been 
reviewed for the last two decades,3,130,131 little is 
known about their specific contribution to AD 
pathogenesis and their mode of action. This is 
mainly due to a lack of small-molecules that can be 
used to track, study, and impact the function of 
these under-studied ABC transporters. 
The present review consists of two parts:  
PART I provides the status quo of ABCA transporters 
in AD and small-molecule modulators – in particular 
intrinsic substrates, natural compounds, 
pharmacological drugs, and synthetic molecules – 
that have been reported to influence ABCA 
transporter function and expression; PART II 
outlines the necessary drug development pipeline 
for the discovery of novel lead structures as 
potential innovative diagnostics and therapeutics 
against AD. This pipeline includes cutting-edge in 
silico methodologies, established in vitro cell assays, 
and necessary in vivo models.  
Collectively, this review contributes to a 
deeper understanding of small-molecule ligands 
that influence ABCA transporter function, 
potentially leading to the development of novel AD 
diagnostics and therapeutics. 
PART I: STATUS QUO 
ABCA transporters: Physiological function and 
implications for AD 
ABCA transporters are ubiquitously present in 
the human body,3,10,13 although differentially 
expressed.10 All of the 12 subfamily members have 
been associated with cholesterol and/or 
phospholipid transport and homeostasis,3,13,132 
except for ABCA4, which is primarily a transporter of 
retinoids.133-138 
In addition to the diseases listed in Table 1, 
ABCA transporters have been described as key 
proteins in several other human disorders, including 
neonatal respiratory distress syndrome (ABCA3),139 
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chronic interstitial lung disease (ABCA3),140 cataract-
microcornea syndrome (ABCA3),141 hypertrichosis 
terminalis (ABCA5),142 or Harlequin ichtyosis 
(ABCA12).143 
However, one major clinical implication for 
ABCA transporters, particularly ABCA1, ABCA2, 
ABCA5, and ABCA7, relates to AD.28,50,52,63 Their 
suggested roles in this major burdensome 
neurodegenerative disease as well as general 
physiological aspects are summarized in the 
following sections. 
ABCA1 
ABCA1 is the prototype of the ABCA 
subfamily,144 was first identified in 1994, and is 
located on human chromosome 9.145 The complete 
genomic sequence of human ABCA1 was reported in 
2000. The ABCA1 gene spans 149 kb comprising 50 
exons, and the resulting protein is 2261 amino acids 
long.146 ABCA1 is located in the plasma membrane 
and is also present intracellularly in the endoplasmic 
reticulum and Golgi apparatus, where it mediates 
the efflux of cholesterol and phospholipids from 
intracellular compartments to extracellular lipid-
free apolipoproteins, mainly apolipoprotein A1 
(APOA1) and to a lesser extend APOA2 and APOE, to 
form high-density lipoprotein (HDL) particles.3,147,148 
The lipidation of APOA1 is preceded by ABCA1 
dimerization.149 ABCA1 thus represents the first and 
rate-limiting step in the reverse cholesterol 
transport pathway, which removes excess 
cholesterol from peripheral tissues via HDL and 
delivers it to the liver for conversion into bile acids 
and subsequent excretion. In contrast to peripheral 
tissues, the physiological role of ABCA1 in the brain, 
where it is expressed in all cell types, is not well 
defined.103 It has been suggested that ABCA1 is 
required for cholesterol transport from glial cells to 
neurons via APOE, which is secreted by glial cells and 
serves as the main lipid acceptor in the brain.103,125 
In vitro and in vivo studies in Abca1 knock-out 
models demonstrated that ABCA1 is essential for 
normal APOE secretion and lipidation in the 
CNS.150,151 Glial cells deficient for ABCA1 showed 
reduced lipid efflux with concurrent lipid 
accumulation as well as decreased APOE secretion, 
with APOE particles being small and poorly lipidated. 
In mice, Abca1 knock-out resulted in dramatically 
decreased brain levels of APOE. Moreover, 
examination of the hippocampi of Abca1-deficient 
mice revealed a decrease in neurite length and 
number of neurite segments and branches, pointing 
to an importance of ABCA1 for neurite integrity.152 
The major genetic risk factor for sporadic AD is 
the allelic state of the APOE genotype, with 
inheritance of the APOE4 allele markedly increasing 
disease risk.153,154 Recently, Rawat et al. investigated 
how APOE4 affected ABCA1 expression and function 
in vitro in astrocytes.155 The authors found that 
APOE4 decreased ABCA1 plasma membrane levels 
and increased ABCA1 co-localization with late 
endosomes via activation of ADP-ribosylation factor 
6, thereby reducing cholesterol efflux and lipidation 
of APOE particles. They corroborated their findings 
in blood-cerebrospinal fluid (CSF) showing that CSF 
from homozygous carriers of the APOE4 allele was 
less efficient in stimulating ABCA1-mediated 
cholesterol efflux compared to CSF from 
homozygous carriers of the APOE3 allele. 
A recent study assessed cholesterol efflux 
capacity of CSF by analyzing AD patients, non-AD 
patients, and control subjects.156 The results 
demonstrated that ABCA1-mediated CSF-
cholesterol efflux capacity was markedly reduced in 
AD but not in non-AD demented patients. However, 
this difference did not depend on APOE4 status. 
Interestingly, ABCA1-mediated CSF-cholesterol 
efflux capacity inversely correlated with total and 
phosphorylated protein tau, suggesting a link 
between the dysfunction of HDL-like particle in CSF 
and neurodegeneration. 
Apart from the indirect link via APOE, a direct 
link between ABCA1 and AD has also been subject to 
investigation. Expression of hippocampal ABCA1 
was elevated on both the mRNA and protein levels 
and was positively correlated with neuro-
pathological changes and dementia severity in AD 
patients.157 The authors of this study suggested that 
the observed upregulation of ABCA1 could be 
interpreted as a compensatory attempt to clear Aβ 
from the brain. Moreover, a variety of studies 
investigated associations between single nucleotide 
polymorphisms (SNP) in the ABCA1 gene and the risk 
for AD,28,108-111 reporting inconclusive results.95,103 A 
meta-analysis of several studies identified the 
ABCA1 rs2422493 (C477T) polymorphism as a risk 
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factor for AD while no association was found for the 
rs2066718 (V771M) or rs1800977 (C14T) 
polymorphisms.111 This risk effect for rs2422493 was 
confirmed in a recent genetic variant association 
study that, in contrast to the meta-analysis, also 
reported an increased AD risk for rs2066718 and a 
decreased AD risk for rs1800977.109 Further genetic 
association studies and meta-analyses are necessary 
to search for potential associations between ABCA1 
polymorphisms and AD risk. 
In a recent AD GWAS, the rs1800978 
polymorphism in the ABCA1 gene was identified as 
the lead SNP in a new genome-wide significant 
locus.158 The association of genetic variants of the 
ABCA1 gene with AD risk was confirmed by exome 
sequencing data analysis from 32,558 individuals.158 
The study identified around 120 variants that have 
an increased frequency in early-onset AD (EOAD; 
1.5%) and late-onset AD (LOAD; 1.1%) cases, 
compared to 0.5% of all controls. The data 
demonstrated that AD-association was mainly 
explained by extremely rare variants, but also by a 
smaller number of more common variants, e.g., 
N1800H.159 Intriguingly, loss of function and 
missense variants in the ABCA1 gene were 
respectively associated with a 4.7-fold (95%CI 2.2-
10.3) and 2.7-fold (95%CI 1.9-3.8) increased EOAD 
risk, and this was lower for LOAD cases suggesting 
that the burden of damaging ABCA1 variants was 
concentrated in younger AD patients. 
Additionally, some long non-coding (lnc) RNAs 
such as lncRNA LOC286367 have been shown to 
affect ABCA1 expression.160 LncRNA LOC286367 and 
ABCA1 are located on the same chromosome but 
are transcribed in opposite directions. A recent 
study demonstrated that LOC286367 reduces 
ABCA1 expression in THP-1 macrophages and 
increases the levels of proinflammatory 
cytokines.160 
The role of ABCA1 in Aβ deposition and 
clearance as well as in Aβ deposits-related memory 
deficits has been extensively investigated in APP-
transgenic mouse models of AD. The lack of ABCA1 
decreased brain APOE levels and either did not 
affect or increased Aβ load.161-163 A recent study 
utilizing shotgun lipidomics experiments 
demonstrated a common APOE isoform-specific 
phospholipid signature between human APOE3/3 
and APOE4/4 AD brains and lipoproteins isolated 
from astrocyte-conditioned media of APOE3 and 
APOE4 mice.164 Interestingly, the lipoproteins 
derived from wild-type and Abca1het mice had 
phospholipid content APOE3 > APOE4 > APOE3het > 
APOE4het suggesting that the combination of ABCA1 
insufficiency and APOE4 genotype decreases APOE 
lipidation even further, thus aggravating APOE4 
effect. These findings suggest that poorly lipidated 
APOE may promote Aβ aggregation.129,161-163 In 
contrast, overexpression of ABCA1 in an APP-
transgenic mouse model resulted in increased 
lipidation, albeit reduced brain levels of APOE and 
decreased Aβ load, implying that highly lipidated 
APOE may reduce Aβ aggregation propensity.127 This 
is supported by findings of Deane et al., who showed 
that different APOE isoforms may differentially 
disrupt Aβ clearance from mice brains.165 A stable 
isotope-labelling kinetic study in an APP-transgenic 
mouse model either lacking ABCA1 or 
overexpressing ABCA1 demonstrated increased 
APOE clearance in both Abca1 knock-out and 
ABCA1-overexpressing mice, but did not reveal any 
effect on Aβ clearance or production, suggesting 
that ABCA1 may regulate Aβ deposition by a 
mechanism other than altering Aβ metabolism.166 In 
contrast, a study assessing the clearance of 
intracerebrally injected 125I-Aβ from the brain 
reported that Abca1-deficiency decreased Aβ 
clearance in non-APP-transgenic mice.167 
Furthermore, knock-out of Abca1 was found to 
augment the dissemination of intracerebrally 
injected, brain-derived Aβ seeds in APP-transgenic 
mice.167 Haplodeficiency of Abca1 led to decreased 
brain APOE levels and increased Aβ oligomer levels 
but did not affect Aβ deposition in APP-transgenic 
mice.168 However, both haplodeficiency and 
homozygous knock-out of Abca1 aggravated 
cognitive deficits in APP-transgenic mice.152,167,168 
Lastly, the lack of one copy of Abca1 exacerbated 
memory deficits, decreased Aβ clearance, and 
increased Aβ load in APP-transgenic mice expressing 
human APOE4 but not in APP-transgenic mice 
expressing human APOE3.169 
ABCA2 
ABCA2 is predominantly, but not exclusively, 
expressed in the brain, where it can be found in glial 
cells and neurons.170-173 On the subcellular level, 
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ABCA2 is located in endo- and lysosomal 
membranes, facilitating the sequestration of waste 
substances into intracellular vesicles.172 In addition, 
it is involved in myelin lipid transport, neural 
development, and macrophage activation.30,174,175 
Genetic variations of ABCA2 were identified as 
a risk factor for EOAD and sporadic AD.52,176 These 
two studies showed a strong correlation between 
rs908832 and AD.52,176 However, a later study could 
not find a link between this SNP and any form of 
AD.177 In addition, ABCA2 mRNA expression was 
upregulated in AD patients compared to controls 
suggesting ABCA2 as a biomarker for differential 
diagnosis of AD.178 Preclinical studies of ABCA2 
suggested that this transporter modulates Aβ 
production via the LDL receptor (LDLR).179,180 ABCA2 
overexpression increased LDLR density, and LDLR 
deficiency has been described to enhance Aβ 
deposition.181 Chen et al. reported a co-localization 
of ABCA2 and Aβ as well as Aβ upregulation in cells 
overexpressing ABCA2. In addition, impairment of 
ABCA2 expression using small interfering RNA 
(siRNA) was accompanied by a decrease in Aβ 
production.182 Abca2 depletion has been shown to 
induce a shift from β- to α-secretases and thus, a 
reduction of APP processing by γ-secretase.182 
Furthermore, ABCA2 has been proposed to play a 
role in Aβ production as it has been reported to 
upregulate sphingosine in murine cells and, 
therefore, to induce APP transcription.183 However, 
another study in human cells could not confirm the 
modulation of Aβ production or cholesterol efflux by 
ABCA2.184 Thus, further research on the role of 
ABCA2 in AD pathogenesis and its potential as a 
therapeutic target is necessary. 
ABCA3 
Despite its initial report of exclusive lung 
expression,185 ABCA3 is also found in other tissues 
including the brain.186,187 Within the brain, the 
highest levels of ABCA3 were found in 
oligodendrocytes.188 
ABCA3 plays a role in producing surfactants in 
the lung, suggesting that the transporter 
may also be involved in lipid metabolism in the 
brain, specifically phosphatidylcholine and 
phosphatidylglycerol transport. Interestingly, 
phosphatidylcholine has also been discussed in the 
context of AD.189 A genetic study revealed that 
mutations in ABCA3 can also cause cataract-
microcornea syndrome, a rare congenital mal-
formation of the eye.141 The actual implications of 
the potential connection between altered ABCA3 
functionality and AD need to be addressed in future 
studies. 
ABCA4 
ABCA4 is mainly expressed in the retina with 
very little presence in other tissues of the CNS.190 
ABCA4 mutation causes Stargardt disease, 
characterized by macular dystrophy, retinal 
alterations, and lipofuscin accumulation.60,61,190,191 
Other retinal diseases, such as fundus 
flavimaculatus, retinitis pigmentosa, or cone-rod 
dystrophy, have also been associated with 
mutations of ABCA4.55,57,58,192 ABCA4 is expressed in 
brain capillary endothelial cells, as well.193 However, 
no link between ABCA4 and AD has been suggested 
to date.  
ABCA5 
ABCA5 is a little-known member of the ABCA 
subfamily expressed mainly in skeletal muscle with 
unknown function in the brain.194 Studies in 
peripheral tissues suggest that the function of 
ABCA5 is associated with cellular lipid 
metabolism.195 Abca5 knock-out in mice induced 
signs of lysosomal storage disease in the heart and 
the thyroid gland.131 
In the brain, ABCA5 is expressed in neurons 
and, to a lesser extent, in microglia, astrocytes, and 
oligodendrocytes.195 Fu et al. showed that ABCA5 
stimulated cholesterol efflux in neurons and induced 
a decrease in Aβ production probably affecting APP 
processing but not its expression.195 
ABCA6 
ABCA6 is ubiquitously expressed with high 
levels in liver, lung, heart, brain, and ovaries. This 
transporter is probably involved in macrophage lipid 
homeostasis as it is upregulated during macrophage 
differentiation and is responsive to cholesterol 
treatment.196 Although certain missense variants of 
ABCA6 have been correlated with blood cholesterol 
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levels,197 no link between ABCA6 and AD has yet 
been found. 
ABCA7 
ABCA7 was first identified in the year 2000, and 
is located on human chromosome 19.198-200 Analysis 
of ABCA7 mRNA expression levels has shown that 
this transporter is mainly confined to the brain and 
the immune system.3 Due to its high homology to 
ABCA1 (54%),200 ABCA7 was first hypothesized to 
play an important role in lipid trafficking, mediating 
cholesterol and phospholipid efflux. ABCA7 actively 
transports phosphatidylcholine, phosphatidylserine, 
and sphingomyelin from the cytoplasm to the 
exocytoplasmic leaflet of membranes.198,199,201 
However, in contrast to ABCA1, ABCA7 generates 
only small HDL particles.202 Recent research has 
shown that lipid trafficking by ABCA7 plays a 
secondary role. Studies in Abca7 knock-out models 
have demonstrated that ABCA7 is involved in the 
phagocytotic activity of macrophages and 
fibroblasts198,203-205 but not in cell cholesterol 
release.206-208  
In 2011, Hollingworth et al. identified the 
ABCA7 gene as an AD risk locus.198,209 In multiple 
studies, variants of ABCA7 have been associated 
with an increased risk of developing AD.198,210-212 In 
2015, Steinberg et al. reported that rare loss-of-
function variants of ABCA7 confer a risk of AD in 
Icelanders (odds ratio: 2.12; P = 2.2 ∙ 10-13), and 
found a similar association in study groups from 
Europe and the United States (combined odds ratio: 
2.03; P = 6.8 ∙ 10-15).213 In particular, the rare AD-
related polymorphism rs200538373 was associated 
with an AD risk odds ratio of 1.9.210 These studies 
suggest that reduced levels of ABCA7 may increase 
the risk of AD. Nonetheless, it is not clear how these 
polymorphisms affect ABCA7 function and 
contribute to AD progression. Increased levels of 
ABCA7 expression were described in AD patients 
and were also positively correlated with cognitive 
decline.198,211 This finding is consistent with Abca7 
mRNA transcription levels in J20 mice.123 The 
increase of ABCA7 may be a compensatory defense 
mechanism that is insufficient to stop disease 
progression. Furthermore, the rs3764650G allele 
has been associated with increased neuritic plaques 
in human patients198,214 and a limitation of the 
neuroprotective effects of exercise intervention.215 
These studies support a potential protective role of 
ABCA7 in AD. To date, three potential roles have 
been identified for ABCA7 contribution to AD: APP 
processing, immune response, and lipid 
metabolism.  
Chan et al. proposed an inhibitory effect of 
ABCA7 on Aβ deposition after showing in vitro 
inhibition of Aβ production independent of β-
secretase activity.120 Other authors proposed that 
ABCA7 is not directly linked to Aβ production, but 
rather through lipid metabolism as ABCA7 mediates 
the transport of lipids across the BBB and ABCA7 loss 
of function may alter cholesterol transport by 
decreasing APOE secretion and ABCA1 expression. 
This alteration in cholesterol metabolism can also 
contribute to AD development.216 However, Abca7 
knock-out induced an increase of Aβ load with no 
difference in clearance rate and an increase of β-
secretase expression. On the other hand, ABCA7 
overexpression led to diminished Aβ production and 
improved cognitive function.217,218  
Nevertheless, ABCA7 is highly expressed in 
phagocytic cells, including macrophages and 
microglia, suggesting a role of the transporter in 
phagocytosis.188,198 Phagocytosis is crucial to 
maintain brain homeostasis. Indeed, ineffective 
phagocytosis may induce neuroinflammation, which 
is a risk factor in AD. In addition, microglial cells are 
involved in phagocytosis and degradation of Aβ. 
Thus, an involvement of ABCA7 in microglial 
phagocytosis of Aβ may explain the contribution of 
this transporter to AD pathogenesis. In AD patients, 
increased ABCA7 transcription has been found in 
areas with plaques but not in unaltered regions such 
as the cerebellum.123 This increase in transcription 
was paralleled by microglia recruitment supporting 
the contribution of ABCA7 to microglia-mediated 
phagocytosis of Aβ. In addition, Abca7 knock-out 
mice showed a reduced microglia response after 
intracerebral Aβ injection.123 Kim et al. demon-
strated an increased Aβ load in J20/A7 knock-out 
mice compared to J20 mice, potentially due to an 
altered phagocytic function.124,198 Furthermore, it 
has recently been shown that Abca7 haplodeficiency 
disturbs the microglial immune response and causes 
enhanced Aβ accumulation in microglia, probably 
due to alterations in endolysosomal trafficking.219 
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Last, a new hypothesis has emerged recently, 
assigning ABCA7 a prominent role in the altered 
lipidostasis hypothesis in AD.104 The authors of this 
study proposed the existence of a neuro-
degenerative lipid that is naturally removed by 
ABCA7. A loss of ABCA7 function due to the 
described polymorphisms might accelerate 
accumulation of this lipid, inducing Aβ aggregation. 
In fact, a link between cholesterol metabolism and 
ABCA7-mediated phagocytosis has been reported, 
which may also explain the protective properties of 
statin treatment in the development of 
AD.105,198,203,220 
Despite recent findings, the role of ABCA7 in 
AD pathogenesis remains unclear. According to in 
vitro and preclinical research, it may be associated 
with phagocytic activity by microglia, which could be 
linked to cell cholesterol metabolism.105,198,203 Thus, 
further investigation is required to reveal the role of 
ABCA7 in AD pathogenesis and its potential use as a 
therapeutic target for this neurodegenerative 
disease. 
ABCA8–ABCA10 
So far, no obvious role of ABCA8–10 has been 
elucidated for AD, neurodegenerative diseases, nor 
any human disease. However, several potential 
intrinsic substrates of ABCA8 have been 
identified.10,221,222 Furthermore, a significant number 
of ABCA transporter modulators have been 
identified on this target.222 Hence, ABCA8 represents 
a good model system for the development of 
potential therapeutics targeting other ABCA 
transporters taking the scarce knowledge on this 
transporter subclass into account. 
ABCA12 
ABCA12 is expressed predominantly in the 
epidermis, and its main function is the transport of 
lipids.223 It is hypothesized that ABCA12 plays a role 
in skin lipid homeostasis. Mutations in this gene are 
associated with lamellar ichthyosis type 2 and 
Harlequin ichthyosis.143,224,225 However, a Japanese 
study investigated common polymorphisms of 
ABCA12 and did not find an association with 
sporadic AD.226 
ABCA13 
ABCA13 is the largest ABC transporter with 
576 kDa.227 It has been reported to be highly 
expressed in the brain as well as in peripheral 
tissues.227 A very small study found reduced neuro-
inflammation and altered ABCA13 expression in post 
mortem analyses of brains from patients with Lewy 
body dementia.64 In addition, increased ABCA13 
expression has been reported after stroke in mice.67 
Furthermore, two studies showed enhanced 
ABCA13 mRNA expression in schizophrenic patients 
after different antipsychotic treatments, suggesting 
a role of this transporter in psychiatric 
disorders.48,65,66 However, no association between 
ABCA13 and AD has been found.  
Modulators of ABCA transporter function, 
trafficking, and regulation 
‘Modulation’ is a widely used term to 
summarize actions of small-molecules that have 
been reported to alter ABCA transporter function, 
trafficking, and/or regulation. Modulators can be 
divided into ‘interactors’ and ‘regulators’.  
Interactors summarize compounds that 
directly bind to ABCA transports, which can have 
either inhibiting or activating effects on the 
transporters. Substrates are also included in this 
category. In terms of ABCA transporters, however, a 
direct interaction of these agents with their target(s) 
has in most cases not yet been comprehensively 
proven. Therefore, compounds that are believed to 
directly interact with ABCA transporters extend the 
category of interactors. Figure 1 represents the 
most prominent interactors of ABCA transporters 
and provides additional information about their 
mode of modulation. 
Regulators are compounds that change ABCA 
transporter expression (transcription and/or 
translation) in terms of induction and/or 
downregulation. In addition, compounds that 
regulate ABCA transporter trafficking can be 
included into the category of regulators, as this 
effect was often observed as ‘pseudo-protein 
increase’ at the cell membrane. Figure 2 depicts the 
most prominent regulators of ABCA transporters 
including proposed mode of modulations. 
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Figure 1. Molecular formulas of prominent interactors of ABCA transporters. 
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Figure 2. Molecular formulas of prominent regulators of ABCA transporters. 
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It must be stated that the term ‘inhibitor’ and 
‘activator’ are often misused in the literature, as in 
most cases studies describe a downregulation or 
induction. In the present review, this mislabeling has 
been taken into account and the present review and 
the respective compounds have been allocated into 
the correct groups. As established earlier,23,24 the 
compounds are sorted according to their origin: (i) 
intrinsic substrates and substrate-like molecules, (ii) 
(other) natural compounds, (iii) pharmacological 
drugs, (iv) high-throughput screening-(HTS)-derived 
candidates, as well as (v) compounds from 
synthetic/medicinal chemistry approaches. Figure 3 
gives a general overview of specific interactors and 
their postulated mode of modulation. Table 2 
summarizes all modulators of ABCA1, the most 
studied ABCA transporter, while Table 3 summarizes 
all known modulators in terms of the other ABCA 
transporters. The stated concentration values are 
indicators of bioactivities of the respective 
compound and are strongly dependent on the 
testing system utilized. Hence, the respective data 
must be interpreted with caution. 
 
Small-molecule interactors of ABCA transporters 
Endo- and xenobiotic substrates 
The most genuine interactors of ABCA 
transporters are intrinsic substrates of these 
transporters. These include cholesterol (Figure 1) 
and other sterol derivatives,10,221,222,228 but also 
phospholipids (Figure 1), sphingolipids228,229 and 
retinoids (e.g., all-trans-retinal; Figure 1).133-138 In 
addition, certain intrinsic molecules were 
demonstrated to interact with ABCA transporters, in 
particular with ABCA1230 and ABCA8.10,221,222 α-
tocopherol (vitamin E) was demonstrated to be 
transported by ABCA1,230 and to interfere with 
ABCA1 regulation.231 The sterol derivatives 
estradiol-β-glucuronide, estrone sulfate, and 
taurocholic acid (Figure 1), but also the physiological 
substrate leukotriene C4 (LTC4), the natural 
compound ochratoxin A, as well as the chemical p-
amino hippuric acid were discovered as (potential) 
ABCA8 substrates.10,221,222 Specifically the ABCA8-




















Figure 3. General overview of proteins participating in ABCA1 regulation and interaction. 
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pancreatic cancer cell lines was suggested as the 
major mechanism behind gemcitabine resistance in 
these cells,221 which was corroborated in HEK293 
cells stably expressing ABCA8.10 
In addition, a small body of evidence suggests 
that ABCA2 and ABCA3 contribute to the subcellular 
sequestration of certain antineoplastic agents into 
endo- and lysosomes.232-235 These agents  
include cytarabine (ABCA3),235 daunorubicin 
(ABCA3),232,233,235 etoposide (ABCA3),235 imatinib 
(ABCA2 and ABCA3; Figure 1),234,236 mitoxantrone 
(ABCA3),235 and vincristine (ABCA3; Figure 1).235 
Furthermore, several antineoplastic agents were 
described to have less effect when ABCA2 was 
overexpressed in vitro171,237,238 and in vivo.239 For 
example, the anticancer drug estramustine 
(Figure 1) was effluxed from ABCA2-overexpressing 
human ovary carcinoma cells, which were less 
susceptible to estramustine treatment than the 
sensitive cell line.171,238 Antisense nucleotide 
treatment against ABCA2 re-sensitized the 
carcinoma cells, further demonstrating a role for 
ABCA2 in mediating drug efflux.238 Furthermore, 
Abca2 knock-out mice had elevated estradiol and 
estrone levels when treated with estramustine.239 A 
similar effect in terms of susceptibility and re-
sensitization was observed for ABCA3-mediated 
transport of miltefosine in Leishmania,240 
doxorubicin resistance in acute myeloid leukemia 
cells,237 and cisplatin as well as paclitaxel resistance 
in several lung cancer cell lines.241 
Strikingly, ABCA2 co-localized with the 
lysosomal-associated membrane protein 1 (LAMP1) 
– an endolysosomal marker – as well as the 
fluorescence probe dansyl-estramustine. This co-
localization indicates a direct sequestration of this 
antineoplastic drug into endo- and/or lysosomes.171 
On the other hand, the susceptibility of ABCA3-
overexpressing CCRF-CEM leukemia cells to the 
antineoplastic agents cytarabine, methotrexate 
(Figure 1), vincristine, but also the anti-
inflammatory drug dexamethasone, was reduced 
compared to their parental counterparts.242 Taken 
together, ABCA2 and ABCA3 are contributors to 
MDR, and the number of potential ABCA2 and 




Table 2. Currently known modulators of ABCA1. 
   
Mode of modulation Name of modulator Effect concentration; concentration range; EC50; dose; ED50 












1.07 µM; 30 mg/kg body weight in mice 
























20 µM; IC50 = 7.0 µM 
1.9–20 µM 
20 µM; IC50 = 18.8 µM 
20 µM; IC50 = 13.6 µM 


















5–10 µM; 4 mg/kg body weight in mice 
Free Neuropathology 2:33 (2021) Pahnke et al. 






















cholic acid analog 14b 
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chromene derivatives 2, 3, and 5 





















































ED50 = 0.956 µmol/kg body weight in mice 
EC50 = 0.035 µM 
EC50 = 0.37–33.42 µM 
5–20 µM 
12.5–50.0 mg/kg body weight in rats 
0.1–1 µM 
10–200 µM 
ED50 = 2.10 µmol/kg body weight in mice 
1000–10.000 µM; 200–400 mg/kg body weight in mice 
12.9–100 µM 
5–40 µM 
0.1–1.0 µM; 0.5–1 mg/kg body weight in mice 
5–10 µM; 20 mg/kg body weight in mice 
25 µM 
25 µM 
10 µM; 10 mg/kg body weight in mice 
5–40 µM 
EC50 = 3.17 µM 
10–40 µM; 60 mg/kg body weight in mice 
8–10 µM; 10 mL/kg body weight in mice 
0.010 µM 
10 µM 
0.0316–1 µM; 20 mg/kg body weight in mice 
40 µM 
0.01–1 µM; EC50 = 0.2 µM 
40 mg/kg body weight in mice 
41.4–165 µM 
50–100 µM 
ED50 = <30 µmol/kg 
10 µM 
20 µM; 50 mg/kg body weight in mice 
2.77–40 µM 
1–20 µM 
1 µM; 0.005–0.02 mg/kg body weight in mice 
100-200 µM 




20 mg/kg body weight in mice 




100 µM; 3 mg/kg body weight in mice 
5–20 µM 
1–20 µM 












0.1–1 µM; ED50 = 31.5 µmol/kg body weight in mice 
2.2–6.6 mg/kg body weight in ferrets 
10 µM 
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Mode of modulation Name of modulator Effect concentration; concentration range; EC50; dose; ED50 












































































0.1–10 µM; 0.3 mg/kg body weight in mice 
50 µM 
30–75 mg/kg body weight in mice 
10 µM 





EC50 = 2.91 µM 
50 µM 
1–20 µM 
1 µM; 1 mg/kg body weight in mice 
EC50 = 0.85 µM 
20 µM; 12.5 mg/kg body weight in mice 
0.04–10 µM; EC50 = 0.29 µM 
0.050 µM 
0.005 µM 
0.05–10 µM; EC50 = 1.49 µM 
5 µM 










0.03–20 µM; EC50 = 0.01391 µM 
10 µM 
2.5–3 µM 




0.75% of high-fat diet in mice 
0.1–25 µM; ED50 = 4.11 µmol/kg body weight in mice 
10 µM 








ED50 = <30 µmol/kg body weight in mice 
0.05–100 µM 
1 µM; 40 mg/kg body weight in mice 
2.5–5 µM 
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0.1–2.5 µM; 8 mg/KG body weight in rats 
0.1 µM 
100 mg/kg body weight in mice 
0.1–100 µM 













100 mg/kg body weight in rats 
25–300 mg/kg body weight in mice 













10 µM; 0.5 mg/kg body weight in mice 

































a u.c. = unspecified concentration 
b u.d. = unspecified dose 
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Interestingly, missense mutations of ABCA4 
were associated with chloroquine- and hydroxy-
chloroquine-associated retinopathy,243 although 
contradictory studies exist.244 A direct interaction 
was postulated, however, not proven. Nevertheless, 
these results suggest chloroquine and hydroxy-
chloroquine as potential ABCA4 substrates. 
Inhibitors  
To date, the number of small-molecules that 
(are believed to) directly interact with ABCA 
transporters is very low. For example, only 14 
inhibitors can be found in the literature regarding 
the most studied prototype of ABCA transporters, 
ABCA1.245-248 Only four of these inhibitors are 
associated with half-maximal inhibition con-
centrations (IC50),245,249 which is the ‘golden 
surrogate’ to evaluate and judge inhibitory activities 
of small-molecules. The following section will 
highlight these small-molecules as well as inhibitors 
of other ABCA transporters. 
ABCA1 
Glibenclamide and 4,4’-diisothiocyano-2,2’-
stilbene-disulfonic acid (DIDS) 
As outlined above, ABCA1 is the most studied 
and understood ABCA transporter, although its 
particular role in neurodegenerative diseases in 
general51,103 – and in AD in particular – is not well 
understood.28-30,43,95,102 However, over time, several 
agents were found to impact ABCA1 transport 
function. The most prominent examples are 
glibenclamide and DIDS (both Figure 1), which were 
first shown to inhibit ABCA1 in 1997.247,248 These 
drugs blocked the ABCA1-mediated 125I efflux from 
murine peritoneal macrophages247 as well as human 
ABCA1-transfected Xenopus laevis Oocytes.248 
Glibenclamide and DIDS inhibited the ABCA1-
mediated transport of cholesterol and other sterols 
as well as phospho- and sphingolipids. Thus, these 
agents became the ‘standard ABCA1 inhibitors’ and 
have frequently been used in ABCA1 studies ever 
since.229,250-269 Glibenclamide and DIDS were 
preferred over other discovered ABCA inhibitors, 
such as bumetanide, diphenylamine 2-carboxylic 
acid, flufenamic acid, furosemide, and 
bromosulfophthaleine.248 Specifically glibenclamide 
was rigorously evaluated regarding its mechanism of 
action. It was demonstrated that glibenclamide 
prevented cross-linking of 125I-marked APOA1 to 
ABCA1,267,270 not interfering with ABCA1 location at 
the cell surface.267 In essence, glibenclamide and 
DIDS may play a significant role in the development 
of future modulators of ABCA transporters in 
general. 
Probucol and cyclosporine A 
Less prominent but also well characterized are 
the antilipidemic drug probucol246,271-278 and the 
immunosuppressant cyclosporine A245,249,258,279-281 
(both Figure 1). Probucol was demonstrated to 
reduce the cholesterol efflux from different  
ABCA1-overexpressing murine and human  
macrophages,275-278 and total lipid release 
(cholesterol + phospholipids) from human WI-38 
fibroblasts.246 Vice versa, probucol increased 
accumulation of free cholesterol, cholesterol esters, 
phosphatidylcholine, and sphingomyelin in human 
fibroblasts.246 Additionally, probucol was reported 
to prevent cell surface-specific binding of 
125I-marked APOA1 to ABCA1.246,278 Similarly, this 
effect has already been demonstrated for 
glibenclamide before.267,270 Interestingly, it was 
shown that total ABCA1 protein levels were 
increased after exposure to probucol due to 
decreased degradation.246,275 This qualifies probucol 
also as a stabilizer. However, as its inhibiting effect 
is far more pronounced, we have included it as an 
inhibitor here. 
The immunosuppressant cyclosporine A has 
been characterized as an ABCA1 inhibitor in multiple 
studies.245,249,258,279-281 This inhibition was shown to 
be direct through a radiolabeled variant of 
cyclosporine A and purified ABCA1.245 Cyclosporine 
A not only functionally inhibited ABCA1-mediated 
cholesterol and phospholipid efflux,245,249 and 
caused intracellular accumulation of cholesterol,258 
but also inhibited the ABCA1-dependent binding of 
Alexa 546- or 125I-labeled APOA1,245,249 as 
demonstrated for glibenclamide267,270 and 
probucol246,278 before. Interestingly, toxicity assays 
demonstrated that cyclosporine A negated the 
positive effect of an ABCA1 inducer on cell viability 
when cells were exposed to Aβ proteins.280 This was 
confirmed in vivo in C57BL/6 mice that had reduced 
HDL levels.249 Interestingly, cyclosporine A was 
shown to decrease ABCA1 turnover, increasing its 
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presence at the cell surface by a factor of two as 
demonstrated with a GFP-labeled ABCA1 variant,249 
suggesting a similar mode of inhibition as for 
probucol.275 Thus, as for probucol,246,275 cyclosporine 
A also appears to have a stabilizer function,275 but is 
included in the current section due to its 
pronounced inhibitory role. Morevover, the 
cyclosporine A analog valspodar (PSC833) inhibited 
direct binding of radiolabeled cyclosporine A to 
ABCA1, revealing that valspodar also acts as an 
ABCA1 inhibitor.245,282 Furthermore, several other 
calmodulin antagonists inhibited ABCA1-mediated 
cholesterol efflux and binding of APOA1.245 These 
include pimecrolimus,245 sirolimus,245 and 
tacrolimus,245 suggesting these molecules as 
potential scaffolds for the development of future 
ABCA1 modulators. 
Other ABCA1 inhibitors 
In terms of other small-molecules that were 
suggested to inhibit ABCA1 function, BLT-4 has been 
demonstrated to inhibit cholesterol and 
phospholipid export from adipocytes and 
macrophages,255 and to decrease cholesterol efflux 
from ABCA1-transfected HEK293 cells. BLT-4 was 
also shown to inhibit 125I-marked APOA1-binding to 
ABCA1,270 as demonstrated for glibenclamide,267,270 
probucol,246,278 and cyclosporine.245,249 
Other ABCA transporters 
While ABCA1 can be considered a less-studied 
ABC transporter with certain knowledge about its 
function and interfering small-molecules,18 all other 
ABCA transporters belong to the group of under-
studied ABC transporters that cannot be addressed 
by small-molecules with very rare exceptions.18 
One rare example is ABCA8. Using the Xenopus 
laevis Oocytes model in vitro testing system,248 
Tsuruoka et al. reported inhibitors of this transport 
protein.222 While digoxin, probenecid, and verapamil 
(all Figure 1) could be identified as very weak 
inhibitors of ABCA8-mediated estradiol-β-
glucuronide transport, dofequidar (MS-209), 
ochratoxin A, and verlukast (MK-571; Figure 1) were 
discovered as moderately potent inhibitors.222 In 
addition, glibenclamide was also suggested to 
(partially) inhibit ABCA8 function.266  
Activators 
Although activators of ABC transporters have 
been reported, as for example, for ABCB123 and 
ABCC transporters,23,283-288 these reports are 
somewhat scarce compared with other classified 
modulators of ABC transporters. In terms of A 
subclass ABC transporters, no small-molecule 
activators are known. However, it is well established 
and has been extensively demonstrated that ABCA1 
activity depends on (co)-administration of HDL 
and/or APOA1.117 HDL and APOA1 are not small-
molecules but peptides, and therefore fall outside of 
the scope of the present review. Similarly, it has 
been shown in several reports that HDL-mimics 
consisting of 26 amino acids are able to increase 
ABCA1-mediated transport.289 Although these 
molecules are also not small-molecules, the 
scarceness of activators of ABCA transporters 
warrants the inclusion of these middle-sized 
molecules here. 
 
Table 3. Currently known modulators of ABCA transporters other than ABCA1. 
   
Mode of modulation Name of modulator Effect concentration; concentration range; EC50; dose; ED50 
   
ABCA2   






















u.d.c in Aphis gossypii 
5 µM 
Downregulators celecoxib 10 µM 
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Mode of modulation Name of modulator Effect concentration; concentration range; EC50; dose; ED50 
   
ABCA3   





























































   
ABCA4   




























   















Downregulators digoxin 2.5 g/kg body weight in mice 
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Mode of modulation Name of modulator Effect concentration; concentration range; EC50; dose; ED50 
   
ABCA7   










2.5 g/kg body weight in mice 
2.48 µM 
   
ABCA8   






























42.04 g/kg body weight in rats 
Downregulators digoxin 2.5 g/kg body weight in mice 
   
ABCA9   
Downregulators digoxin 2.5 g/kg body weight in mice 
   
ABCA12   


























Stabilizers acitretin 1–10 mg/kg body weight in pigs 
 
a apart from cholesterol and/or phospholipids 
b u.c. = unspecified concentration 
c u.d. = unspecified dose 
 
 
In 2004, structural elements of APOA1 were 
discovered to promote ABCA1-mediated cholesterol 
efflux.290 In 2007, Vedhachalam et al. discovered 
that the C-terminus of APOE promoted ABCA1-
mediated efflux from murine J774.A1 macro-
phages.291 The latter discovery led to the 
development of two short-length peptides, ATI-
5261 and CS-6253, consisting of 26 amino acids 
each.289 Their amino acid sequences expressed in 
single-letter code are EVRSKLEEWFAAFREFAEE-
FLARLKS289 and EVCitSKLEEWLAALCitELAEELLACit-
LKS (Cit = citrulline),292 respectively, which is of 
particular interest for the development of novel lead 
structures. Both peptides increased ABCA1-
mediated cholesterol and phospholipid transport in 
murine and human macrophages.289,292 
Interestingly, CS-6253 decreased 125I-labed APOA1 
binding to ABCA1,292 as demonstrated for 
glibenclamide,267,270 probucol,246,278 cyclosporine 
A,245,249 and BLT-4270 before. However, CS-6253 was 
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shown to compete with APOA1 to promote ABCA1-
mediated transport.292 Both ATI-5261 and CS-6253 
have a high practical relevance regarding AD and 
other neurodegenerative diseases, as these agents 
demonstrated in vivo efficacy.289,293 ATI-5261 
treatment of high fat diet-fed Apoe knock-out mice 
decreased cholesterol levels in both plasma and 
feces and reduced atherosclerotic lesions.289 For CS-
6253, a reduction of Aβ42 levels and tau protein 
phosphorylation in transgenic humanized APOE4 
mice was demonstrated, which was accompanied by 
improved cognitive functions.293 Interestingly, an 
elevation of ABCA1 protein was also observed in 
treated mice.293 Indeed, a stabilization and/or 
induction may also have contributed to the 
observed effects. However, the proven direct 
binding of these agents suggested that activation 
takes place as the major mode of action. 
Nonetheless, CS-6253 has not been tested in AD 
mouse models so far, and being a peptide, it would 
not be suitable for oral application in patients. 
Small-molecule regulators of ABCA transporters 
The herein discussed regulators interfere with 
ABCA transporter expression and/or trafficking. 
Important representatives are depicted in Figure 2 
and additional information is given in terms of their 
mode of modulation. Since many different pathways 
are involved in ABCA transporter regulation, 
Figure 3 provides a general overview of participating 
proteins and protein families in terms of the most 
studied ABCA transporter, ABCA1. 
Inducers 
ABCA1 - LXR and RXR pathways 
Given the findings in AD mouse models with 
knock-out of ABCA1/Abca1 or overexpression of 
ABCA1, upregulating ABCA1 activity may be a 
therapeutic strategy for decreasing Aβ pathology in 
AD. ABCA1 is under the transcriptional control of the 
nuclear receptors liver-X-receptor (LXR) and 
retinoid-X-receptor (RXR),294-296 which can be 
targeted by small-molecule agonists of LXR and RXR 
to induce ABCA1 expression (Figure 3). Numerous 
studies reported that treatment of APP-transgenic 
mice with LXR or RXR agonists decreased Aβ 
load126,297-301 and/or improved cognitive 
impairment.126,297,298,300 Other studies reported 
cognitive improvement without significant changes 
in Aβ load in APP-transgenic mice treated with LXR 
agonists.302,303 LXR and RXR agonists have already 
been described extensively as potential therapeutics 
in the literature, also with respect to AD.304 The 
present review will focus on those agonists that 
were reported in clear association with ABCA1. 
Oxysterols and retinoic acids 
22-(R)-hydroxycholesterol (Figure 2) has been 
established as the natural gold standard for 
ABCA1/Abca1 induction through LXR acti-
vation,122,205,249,252,259,262-264,268,277,278,305-315 while 9-cis 
retinoic acid (Figure 2) became the natural gold 
standard for RXR activation.122,245,249,259,262,264,277,278, 
309,311,313,316 The inducing effects were described both 
on ABCA1/Abca1 mRNA122,205,252,263,264,305,307-311,313,315-
317 and ABCA1 protein levels.122,252,263,264,306,309-
311,316,318 
Other oxysterols like 4-hydroxycholesterol, 20-
(S)-hydroxycholesterol, 22-(S)-hydroxycholesterol, 
24-hydroxycholesterol, 24-(S)-hydroxycholesterol, 
25-hydroxycholesterol, 27-hydroxycholesterol, and 
cholesterol itself also induced ABCA1/Abca1 
mRNA205,305,313,315,319-327 and ABCA1 protein 
levels.321,328 The increase in ABCA1 protein was 
functionally confirmed by an enhanced 
cholesterol305,306,313,315,318 and phospholipid 
efflux,311,318 as well as reduced total cholesterol 
influx.305 Specifically 22-(R)-hydroxycholesterol and 
cholesterol induced both LXRA/Lxra and 
LXRB/Lxrb.310,321 Additionally, cholesterol also 
induced murine peroxisome proliferator-activated 
receptor γ (PPAR-γ) mRNA (Pparg),321 which 
represents an important alternative pathway for 
ABCA1/Abca1 induction. Furthermore, 24-(S)-
hydroxycholesterol reduced in parallel the sterol 
regulation element-binding protein 2 (SREBP2) gene 
expression (Srebp2).323 The SREB protein family also 
represents another important pathway in 
ABCA1/Abca1 regulation. 
The 9-cis-retinoic acid derivative all-trans-
retinoic acid (ATRA) significantly increased 
ABCA1/Abca1 mRNA and ABCA1 protein content in 
murine and human macrophages, which was 
paralleled by increased LXRA mRNA levels in human 
macrophages.329 This increase resulted in a 
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subsequently enhanced cholesterol efflux from 
murine macrophages. ATRA is an agonist of the 
retinoic acid receptor (RAR),329 which is in close 
relation to the RXR receptor and a potential target 
of retinoic acid derivatives. 
TO901317 and GW3965 
The synthetic gold standard and most studied 
ABCA1/Abca1 inducer in the literature is TO901317 
(often referred to as ‘T0901317’; Figure  2).205, 
245,250,252,259,260,262,264,271,272,279,280,282,308,310,317,319,322,324,32
6,328-345 TO901317 targeted both the LXR-α250, 
310,328,330,332,335,337-340,342 and LXR-β pathways,250, 
310,338,342 which correlated to ABCA1/Abca1 induction 
on mRNA and ABCA1 protein levels.205,250,279,282, 
310,319,322,324,326,328,330-335,337-340,342,343 In addition, an 
induction of SREBP1C/Srebp1c has also been 
observed.336,342 Functionally, TO901317 increased 
cholesterol efflux,250,259,260,262,264,282,319,324,329,331,342 de-
creased intracellular Aβ content, and increased Aβ 
secretion from different murine brain cells.126,345 
Further, it reduced Aβ25-35-mediated toxicity toward 
cells by induction of Abca1.280 In addition, TO901317 
mitigated memory deficits in high-fat diet-fed APP23 
mice, reducing both plaque and soluble Aβ protein 
levels.344 Besides, TO901317 reduced methionine-
(homocysteine)-induced atherosclerotic lesions in 
Apoe knock-out C57BL/6 mice.335 These findings 
were paralleled by an increase of Abca1 mRNA and 
ABCA1 protein content,335 suggesting a potential 
relevance of TO901217 in AD therapy, although it 
must be taken into account that LXR activators, in 
particular TO901317, were demonstrated to have 
severe side effects in mice, such as neutropenia, 
hypertriacylglycerolemia, hepatic triacylglycerol 
accumulation, and hepatic steatosis.271,346,347 
The second most common synthetic 
 LXR-α and LXR-β agonist is GW3965 
(Figure 2).255,272,317,319,321,334,348-352 GW3965 increased 
mRNA317,319,321,348,349,351,352 and protein levels255,272,351 
in different ABCA1-expressing cells. Functionally, 
increased Abca1 mRNA and ABCA1 protein levels 
correlated with enhanced cholesterol efflux.255,351 
Strikingly, exposure of murine BV2 microglia to 
GW3965 reduced Aβ42 levels due to an enhanced 
degradation of Aβ42,126 suggesting that ABCA1 
contributes to general Aβ degradation. Finally, 
GW3965 significantly increased Abca1 transcription 
in C57BL/6 mice,334,351 and improved contextual 
memory as well as Aβ pathology in TG2576 mice,126 
emphasizing its high relevance in AD therapy. 
ABCA1 - other LXR agonists and inducers 
Sterane and sterane-like natural compounds 
Several sterane derivatives were demonstrated 
to target LXR-α and LXR-β activation253,307,310,353 
and/or LXRa/Lxra and LXRB/Lxrb upregu-
lation,330,332,354,355,356,357 resulting in induction of 
ABCA1/Abca1. Celastrol,330,332 digoxin,253 fuco-
sterol,308 certain gypenosides,354 ouabain,253 platy-
codin D,355 saikosaponin A,356 24-(S)-saringosterol,307 
24-(S)-stigmast-5-ene-3β,24-diol,307 taxarasterol,353 
testosterone,357 and TR1310 increased ABCA1/Abca1 
mRNA307,308,310,330,332,353,354,356,357 and/or ABCA1 
protein content310,253,353,354,355,357 leading to an 
enhanced efflux of cholesterol in vitro253,308,330,332 
and decreased intracellular cholesterol and/or 
phospholipid levels in vitro330,332,354,356,357 and in vivo 
in mice.253 The effect of fucosterol was comparable 
to that of the standard ABCA1/Abca1 inducer 
TO901317.308 A correlation to SREBP1(C) 
upregulation308,307,357 and SREBP1 protein 
expression357 could be determined in case of 
fucosterol,308 24-(S)-saringosterol,307 24-(S)-
stigmast-5-ene-3β,24-diol,307 and testosterone.357 In 
case of celastrol, the regulation of intracellular 
cholesterol was pinned to an activation of 
autophagy330,332 and lipophagy,330 which are 
processes that may be associated with Aβ 
degradation. 
Flavonoids 
The flavonoids naringenin,339 quercetin,358 and 
vitexin359 increased ABCA1/Abca1 mRNA339,359 and 
ABCA1 protein levels339,360,358 by induction of 
LXRA/Lxra mRNA358,359 and LXR-α protein.339,360 The 
effect of naringenin and the standard ABCA1/Abca1 
inducer TO901317 were additive. Naringenin was 
shown to be dependent on the cAMP-activated 
protein kinase (AMPK) regulation (AMPK), as well as 
SREBP1C regulation.339 The AMPK pathway is 
another very important regulator of ABCA1 
expression. Functionally, cholesterol efflux from 
human339,360 and murine360 macrophages was 
increased in the presence of naringenin.339,360 In 
vivo, naringenin and quercetin induced Abca1360 and 
ABCA1,361,362 as well as ABCA1-mediated cholesterol 
transport,360 which was reflected in reduced 
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atherosclerotic lesions in the aorta of high-fat diet-
fed C57BL/6 mice.360 In terms of quercetin, a protein 
increase of LXR-α and PPAR-γ was observed.361 
Chalcones, the precursors of flavonoid 
biosynthesis, were also demonstrated to intervene 
with ABCA1 expression. The chalcone derivatives 
1h,363 1m,363,364 and 1m-6364 were demonstrated to 
increase ABCA1 mRNA and ABCA1 protein levels in 
THP-1 macrophages,363,364 which was accompanied 
by an increase in LXRA mRNA and LXR-α protein 
levels.363 The intracellular lipid content was 
decreased, while the cholesterol efflux was 
increased after exposure of THP1-cells to 1m-6.364 In 
addition, SREBP1 mRNA was increased by 1m-6,364 
and aortic atherosclerotic plaques were reduced in 
Ldlr knock-out C57BL/6 mice.364 
Polyphenols and diterpenoid natural compounds 
The polyphenols kuwanon G,365 paeonol,252 the 
Celtis biondii-derived compound ethyl 2,4,6-
trihydroxybenzoate,342 and the diterpenoid 
farnesin366 increased ABCA1/Abca1 mRNA252,342, 
365,366 and ABCA1 protein252,342,365,366 content in an 
LXR-α-252,366 and LXR-β-dependent342 manner, which 
in parallel reduced cholesterol content252 and 
increased ABCA1-mediated cholesterol efflux in 
various cell lines.252,342,366 In vivo, farnesin increased 
ABCA1 protein content and cholesterol efflux in 
Apoe knock-out C57BL/6 mice in primary peritoneal 
macrophages and the aorta, which was reflected in 
reduced atherosclerotic plaques.366 
Other natural compounds 
Several other natural compounds induced 
ABCA1/Abca1 targeting LXR-α and LXR-β 
activation256,272,256,349,367 and/or LXRA/Lxra and 
LXRB/Lxrb induction.331,348,350,368,369,370,371,372,373,374 
The garlic ingredient allicin,350 the alkaloid 
berberine,256 the coumarin bergapten A,368 certain 
Pestalotiopsis neglecta-derived chromene deri-
vatives,348 the Rheum palmatum-derived anthra-
quinone danthron,369 the lacton 1,6-O,O-
diacetylbritannilactone,371 epigallocatechin gallate 
(EGCG),370 the glycoside geniposide,375 the vegetable 
ingredient phenethyl isothiocyanate,373 the caro-
tenoid lycopene,372 the Pestalotiopsis neglecta-
derived hydroquinone pestalotioquinoside C,349 the 
alkaloid rutaecarpine,367 selenium,374 the macro-
lactone soraphene A,272 and vitamin  
D3331 led to increased ABCA1/Abca1 
mRNA256,272,331,348,369,256,367,370,372,373 and ABCA1 
protein256,272,331,349,350,368,369,256,367,371,373,374 content in 
vitro331,349,350,369,375,374 and in vivo,368,369,370,371,372,373 
enhancing cellular cholesterol efflux256,272,256,367,369 
and reducing intracellular cholesterol con-
tent.331,350,369,256,367,375,372,374 Danthron also increased 
AMPK protein levels,369 while EGCG downregulated 
Srebp1 mRNA and SREBP1 protein content.370 
Lycopene induced Ppara mRNA in tobacco 
carcinogen- and cigarette smoke-exposed ferrets,372 
while isothiocyanate induced Pparg mRNA as well as 
PPAR-γ protein content in high fat diet-fed C57BL/6 
mice.373 The inducing effects on ABCA1 expression 
of vitamin D3 and TO901317 were additive.331 
Danthron, EGCG, geniposide, and rutaecarpine 
demonstrated also reduced atherosclerotic lesions 
in Apoe knock-out C57BL/6 mice,369,370,375,367 and 
isothiocyanate ameliorated the aortic injury of the 
high-fat diet in the same mice.373 
Pharmacological drugs 
Several pharmacological drugs also 
demonstrated an induction of ABCA1/Abca1 
through LXR-α and/or LXR-β, including the α1-
blocker doxazosin,376 the 5-HT3 receptor antagonist 
ondansetron,279 and the anesthetic propofol.377 
Consequently, increased Abca1 mRNA279,376 and 
ABCA1 protein279,376 levels were observed in 
human279,377 and murine279,376 macrophages376,377 as 
well as astrocytes.279 Functionally, ondansetron 
induced APOE efflux,279 while propofol led to 
increased cholesterol efflux.377 In addition, propofol 
increased PPARG mRNA and PPAR-γ protein content 
in human macrophages.377 
Furthermore, certain antineoplastic agents 
interfered with ABCA1 expression via LXR-α and/or 
LXR-β. Doxorubicin demonstrated an Lxr activation 
with subsequent induction of Abca1 mRNA and 
ABCA1 protein in vitro and in vivo.250 Functionally, 
doxorubicin elevated cholesterol export in vitro. It 
was shown that intra- and extracellular levels of 
cholesterol, cholesterol precursors, and several 
oxysterols were elevated after exposure to 
doxorubicin. These precursors included lathosterol, 
lanosterol, and desmosterol, while the oxysterols 
included 7-α-hydroxycholesterol, 7-β-hydroxy-
cholesterol, 7-ketocholesterol, 24-hydroxycho-
lesterol, and 27-hydroxycholesterol. The authors 
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suggested that doxorubicin exposure induced 
cholesterol metabolism subsequently leading to an 
induction of ABCA1. Besides, idarubicin augmented 
also Abca1 mRNA levels in vitro. 
Synthetic compounds and HTS hits 
Other synthetic compounds have been shown 
to induce ABCA1/Abca1 expression by LXR-α and/or 
LXR-β induction. The polymer pyrrole-imidazole-
polyamide activated a promoter region for Abca1 
expression and thereby increased cholesterol and 
lipid efflux from RAW264.7 cells.376 The authors 
confirmed their findings in vivo, revealing increased 
Abca1 mRNA and ABCA1 protein content in 
peripheral blood mononuclear cells and the liver in 
C57BL/6 mice after exposure to pyrrole-imidazole-
polyamide. 
In addition, the LXR agonist LXR623 induced 
ABCA1 mRNA and ABCA1 protein levels in two 
human renal adenocarcinoma cell lines334 as well as 
Abca1 mRNA levels in vivo in C57BL/6 mice.378 This 
induction was reflected in reduced intracellular 
cholesterol and triglyceride levels. 
It must be noted that several other synthetic 
LXR-α and LXR-β agonists induced Abca1 expression 
in vivo: AZ1–AZ9, AZ876, BMS-852927, F1, 
WAY254011.378 Finally, an HTS approach discovered 
two LXR-α and LXR-β agonists as novel small-
molecule ABCA1/Abca1 inducers: F4 and M2.319 
Synthetic approaches 
A few synthetic approaches have aimed 
 toward the development of ABCA1/Abca1 
inducers.271,336,352,379-382 The cholic acid analog 14b,336 
the thiophene derivative CL2-57,271 as well as 
derivatives of N-benzothiazolyl-2-benzene-
sulfonamide,379 ginsenoside,352 and rutaecarpine,367 
all induced ABCA1/Abca1 mRNA336,352,381 and ABCA1 
protein271,336,379,381 content in vitro271,336,379 and in 
vivo,271 targeting the LXR-α/LXR-β pathway352 by 
activation271 or induction336 of LXR-α/LXRA/Lxra 
and/or LXR-β/LXRB/Lxrb. In vitro, cholesterol efflux 
increased379,381 and intracellular cholesterol as well 
as lipid content were reduced,336,352 while plasma 
and liver triglycerides levels were reduced in vivo in 
high fat diet-fed C57BL/6 mice.271 Interestingly, 14b 
induced farnesoid-X-receptor (FXR) transcription 
(Fxr),336 and CL2-57 inhibited RXR-β, PPAR-γ, and 
PPAR-δ,271  
Finally, Singh et al. described highly potent LXR-
α and LXR-β agonists with effect at concentrations in 
the nanomolar range.382 The described podocarpic 
acid derivatives have not yet been demonstrated to 
induce ABCA1. However, these compounds were 
designated as potential ABCA1 inducers by the 
authors,382 and their high potency makes them 
interesting candidates for further evaluation. 
Such synthetic approaches should be 
highlighted,271,336,352,379-382 as chemical derivatization 
of ABCA1 inducers and elucidation of their 
structure-activity relationships (SAR) have not yet 
been comprehensively assessed. More reports are 
needed to gain innovative molecules that can be 
considered clinically for the treatment of various 
ABCA1-related diseases.  
ABCA1 - other RXR agonists and inducers  
In terms of synthetic RXR agonists, the 4-
chromanon derivatives SPF1 and SPF2 increased 
Abcb1 mRNA and ABCA1 protein levels and lowered 
Aβ25–35-mediated cell toxicity in vitro.280 The same 
effect was observed for the RXR agonist 
bexarotene,280 an FDA approved drug against T-cell 
lymphoma-related cutaneous malformations. 
Bexarotene was used as a standard inducer of 
ABCA1/Abca1 via the RXR pathway in several 
studies.271,272,280,319,380 Induction of Abca1 mRNA and 
ABCA1 protein levels was maximal for bexarotene in 
combination with TO901317.280 Bexarotene is of 
particular practical relevance as a potential 
treatment against AD due to its in vivo effects. In 
different AD mouse models, bexarotene increased 
Abca1 mRNA and ABCA1 protein levels, but also 
reduced cerebral load of Aβ and 
hyperphosphorylated protein tau, which is also a 
histological marker in AD and other dementias.297,383 
This prospect led to synthetic bexarotene 
derivatives, specifically Z10 and Z36.380 Both 
candidates induced ABCA1 protein expression by 
RXR-α activation and reduced Aβ burden in the 
hippocampus of female APP/PS1 mice. This 
coincided with an enhanced ABCA1 protein 
expression in BV2 cells. 
Moreover, the pan-RAR agonist TTNPB also 
increased ABCA1 protein content in murine 
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macrophages in an RXR-α-dependent manner. 
However, the effect was generally smaller compared 
to the effect of ATRA.329 Finally, a combination of the 
LXR and RXR agonists RO0721957 and RO0264456 
increased ABCA1 mRNA in THP-1 macrophages 
accompanied by increased cholesterol efflux.384 
RO0264456 was demonstrated to increase ABCA1 
protein content in combination with TO901317.260 
ABCA1 – protein kinase C (PKC), AMPK, and p38 
mitogen-activated protein kinase (MAPK) 
An alternative approach to induce ABCA1 is 
targeting the PKC pathway (Figure 3). PKC agonists 
were extensively used to induce ABCA1/Abca1 
mRNA and ABCA1 protein 
levels.230,248,249,255,265,266,273,278,289-292,384-387 Prominent 
PKC agonists include cAMP313 as well as synthetic 
derivatives, such as 8-Bromo-cAMP (8-Br-cAMP; 
Figure 2),230,249,255,266,290,292 8-(4-chlorophenylthio)-
cAMP (CPT-cAMP),273,291,384 and dibutyryl-
cAMP.385-387 The observed effects ranged in the 
same order of magnitude as the combination of 22-
(R)-hydroxy-cholesterol and 9-cis-retoic acid.313 The 
increase in ABCA1/Abca1 mRNA and ABCA1 protein 
levels was reflected in an enhancement of ABCA1-
mediated cholesterol and phospholipid 
efflux,249,255,386 and increased APOA1 binding to 
murine RAW264.7 macrophages.385-387 Similar 
observations have been made for the PKC stimulant 
phorbol 12-myristate 13-acetate (PMA), which 
induced ABCA1 protein expression and ABCA1-
mediated cholesterol and phospholipid release.386 
PMA is also the standard substance used to 
differentiate human monocytic leukemia cells into 
THP-1 macrophages – a standard host system for 
ABCA transporter evaluation.231,245,249,256,268,272,275, 
292,308,310,312-316,321,328,335,338,339,341,342,360,363,364,366,377,384,38
8-397 
Regarding the AMPK pathway (Figure 3), the 
natural compound curcumin induced ABCA1/Abca1 
mRNA338,388 and ABCA1 protein levels388,394 as well as 
cholesterol efflux338,388,394 in THP-1338,388,394 and 
RAW264.7394 macrophages, which was also 
mediated through LXR-α activation.338 However, 
these LXR-α activating effects were much more 
pronounced in combination with the gold standard 
TO901317.338 Other AMPK-targeting agents are 
A-769662 and metformin,398 which induced 
ABCA1/Abca1,398 LXRA/Lxra,396,398 and LXRB/ 
Lxrb396,398 in human398 and murine (primary) 
macrophages,398 leading to increased cholesterol 
efflux.396  
Concerning the MAPK pathway (Figure 3), the 
sterane glycoside ginsenoside compound K 
increased Abca1 mRNA and ABCA1 protein levels in 
murine macrophages, reducing intracellular lipid 
content and promoting autophagy.399 These effects 
were pinned to a negative impact on the MAPK 
pathway. Finally, a synthetic inhibitor of MAPK, 
SB203580, was shown to induce ABCA1 protein in 
combination with the above mentioned geniposide 
in vitro in murine macrophages.375 
ABCA1 - the PPAR Pathway 
Another well-known approach to induce 
ABCA1 involves the PPAR pathway 
(Figure 3).268,272,295,309,315,321,326,327,337,343,395,400-409 Cer-
tain PPAR/Ppar inducers and/or PPAR activators 
have been described above, as these modulators 
also have effects on the LXR pathway.321,361,372,373,377 
Several natural compounds target the PPAR 
pathway, such as the flavonoids homo-
eriodictyol,402 hesperetin-7-O-β-D-glucopyrano-
side,402 scutellarein,403 and the antimycotic 
trichostatin A.410 These compounds increased 
Abca1402 and Pparg402 mRNA as well as ABCA1,402,410 
PPAR-α,403 and PPAR-γ402,410 protein levels in 
vitro402,410 and in vivo.403 Decreased intracellular 
cholesterol levels were also observed.402 
Trichostatin A reduced aortic atherosclerotic 
plaques in high-fat diet-fed Apoe knock-out mice,410 
and an upregulation of ABCA1, PPAR-γ, and LXR-α/β 
protein levels was observed in aortic cells as well as 
peritoneal macrophages.410 
Several drugs and drug-like PPAR agonists were 
revealed to induce ABCA1/Abca1 mRNA and/or 
ABCA1 protein content, including the PPAR-α 
agonists fenofibrate,326,400,404 pemafibrate 
(K-877),405 Wy14643,268,343 and RPR-5,268 as well as 
the PPAR-γ agonists efatutazone,337 pioglita-
zone,272,309,326,395,407 pitavastatin,343 prostaglandin J2 
(PG-J2),268,327 rosiglitazone (Figure 2),268,309,315,408,409 
troglitazone,268 and GW7845,315 but also the broad-
spectrum PPAR-α, PPAR-β, and PPAR-γ agonist 
bezafibrate268,327 and the multitarget PPAR-α, PPAR-
γ, and PPAR-δ agonist tetradecylthioacetic acid.401 
This induction was observed for ABCA1/Abca1 
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mRNA268,315,343,401,405 as well as ABCA1 protein 
levels,268,337,343,395,405,409 and was functionally 
confirmed by increased cholesterol efflux.268,315 A 
connection between the PPAR and LXR pathways 
has also been drawn,268,326,327,337,400 highlighting the 
importance of both pathways for ABCA1/Abca1 
induction. Furthermore, fenofibrate had a positive 
impact on both the LXR-α and AMPK pathways400 
Certain PPAR agonists have been used as standard 
inducers of Abca1, e.g., pioglitazone407 and 
rosiglitazone.408  
Synthetic PPAR agonists were also reported to 
induce ABCA1.406 The benzothiazole derivative 
E3317 dose-dependently increased ABCA1/Abca1 
mRNA and ABCA1 protein levels though PPAR-γ 
activation in several cell lines.406 This was reflected 
in decreased cholesterol efflux and reduced 
intracellular cholesterol content. Finally, a 
molecular docking approach to discover novel PPAR 
agonists has yielded GQ-11, which induced Abca1 
mRNA in livers of C57BL/6 Ldlr knock-out mice.407 
ABCA1 - the 3-hydroxyl-3-methyl glutaryl-(HMG)-
CoA-reductase pathway 
Other targets for ABCA1/Abca1 induction are 
the 3-hydroxyl-3-methylglutaryl-(HMG)-CoA-reduc-
tase and cellular cholesterol synthesis 
(Figure 3).318,343 Several HMG-CoA-reductase 
inhibitors such as atorvastatin (Figure 2),330,343,362 
fluvastatin,312,411 mevastatin (compactin),318 
pitavastatin,318,343 and simvastatin312,343 increased 
ABCA1/Abca1 mRNA312,343 and ABCA1 protein 
levels,362,411 as well as ABCA1-mediated cholesterol 
efflux.318 These data are surprising, as one might 
expect the loss-of-function of an enzyme in the 
cholesterol synthesis pathway to induce a decrease 
of ABCA1, preventing cholesterol depletion from 
cells.314384,412 Conversely, the overproduction of 
cholesterol leads to the opposite effect, as 
demonstrated for mevalonate, which is a building 
block of cholesterol synthesis413 and has been 
demonstrated to increase ABCA1/Abca1 mRNA312,314 
and to abrogate Abca1 downregulation.312 
Pitavastatin addressed SREBP-driven promotor 
regions upregulating Abca1 mRNA levels,343 and 
atorvastatin reduced atherosclerotic plaques in 
Apoe knocked-out C57BL/6 mice by induction of 
ABCA1 protein content in the murine aorta.362 
Other ABCA1 inducers 
Sterane and sterane-like natural compounds 
Several other agents were reported to induce 
ABCA1/Abca1 mRNA and/or ABCA1 protein level(s), 
with some studies reporting a unique mechanism of 
action for these agents. Such compounds include 
the sterane derivative ponasterone A (ecdysone; 
ABCA1 protein; ABCA1-mediated cholesterol and 
phospholipid transport),202 and the enoxolone 
derivative glycyrrhizine (ABCA1 protein).414 In 
addition, the sterane derivative and farnesoid-X-
receptor (FXR) activator obeticholic acid induced 
Abca1 mRNA levels in vivo in the ileum of Srb1-
deficient C57BL/6 mice.415 In THP-1 macrophages, 
the sterane-like maslinic acid induced ABCA1 mRNA 
levels, paralleled with an increased cholesterol 
efflux from these cells.390 Finally, the Salvia 
miltiorrhiza-derived tanshindiol C was demon-
strated to induce peroxiredoxin 1 mRNA (Prdx1) and 
protein (PRDX1) content in murine RAW264.7 
cells.416 Prdx1 was demonstrated to regulate Abca1 
mRNA and ABCA1 protein expression. A reduction of 
intracellular cholesterol levels in murine peritoneal 
macrophages could also be observed.  
Flavonoids 
The flavonoids daidzein (Figure 2),309 
kaempferol,397 and pratensein309 induced ABCA1 
mRNA309,397 and ABCA1 protein levels309 as well as 
ABCA1-mediated cholesterol efflux.397In addition, 
hesperetin-7-O-rutinosid (hesperidin) abrogated the 
negative effect of varenicline on ABCA1 protein 
expression in RAW264.7 macrophages.417 The 
authors could underpin their findings with a 
reduction of aortic atherosclerotic plaques in Apoe 
knock-out C57BL/6 mice along with reduced lipid 
levels in peritoneal macrophages derived from these 
mice.  
Polyphenols and polyphenol-like natural 
compounds 
Several polyphenols and polyphenol-like 
compounds induced Abca1 mRNA408,418 and ABCA1 
protein393,404 levels in murine393,404,408,418 and 
human393 macrophages, leading to an increased 
cholesterol efflux.404,408,418 These include certain 
Cannabis sativa-derived stilbenoids404 as well as the 
Tadehagi triquetrum-derived phenylpropanoid 
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glycosides urolithin A418 and urolithin B (sulfate).393 
In vivo, atherosclerotic plaques were reduced after 
urolothin B treatment. One phenylpropanoid 
glycoside was demonstrated to increase Lxra, but 
none of the other compounds could confirm these 
results. Given that the effect of all compounds on 
ABCA1 expression was similar, it is likely that 
another, yet unknown pathway was the major 
contributor to the observed effects.  
Other natural compounds 
Sodium butyrate induced Abca1 mRNA and 
ABCA1 protein levels in murine RAW264.7 cells, 
accompanied by an increased efflux of cholesterol 
from these cells.419 This induction was reflected by 
increased ABCA1 protein content in vivo, reduced 
plasma cholesterol and triglyceride levels, and 
reduced aortic atherosclerotic lesions and hepatic 
steatosis in high fat diet-fed Apoe knock-out 
C57BL/6 mice.  
Pharmacological drugs 
Several pharmacological drugs induced 
ABCB1/Abca1 mRNA309,420,421 and ABCA1 
protein,309,391,421 including the anti-obesity drug 
orlistat,391 the antibiotic sulfoxaflor,420 the 
leukotriene receptor antagonist zafirlukast,421 as 
well as the anthracyclines aclarubicin309 and 
pyrromycin.309 Zafirlukast in particular reduced 
intracellular cholesterol and lipid content in oxidized 
LDL-(oxLDL)-induced lipid-overloaded RAW264.7 
macrophages, and increased cholesterol efflux from 
these cells.421 
Finally, it should be highlighted that 
mifepristone has frequently been used in a 
mifepristone-inducible transfection system to 
stabilize and increase ABCA1 expression in ABCA1-
transfected baby hamster kidney (BHK)-21 cells. This 
ABCA1 induction could be functionally confirmed by 
increased ABCA1-mediated cholesterol and 
phospholipid efflux.245,273,422 
Synthetic compounds, HTS hits, and synthetic 
approaches 
The purinergic P2Y7 receptor antagonists AZ-1, 
AZ-2, and AZ10606120 increased ABCA1 mRNA and 
ABCA1 protein levels and resulted in enhanced 
cholesterol efflux from human CCFSTTG1 
astrocytoma cells.423 The polychlorinated biphenyl 
quinone 2,3,5-trichloro-6-phenyl-[1,4]-benzo-
quinone (PCB29-pQ)424 and the fluorescigenic 
pyrazoline derivative 5 (FPD5)425 increased Abca1 
mRNA424 and ABCA1 protein425 content in RAW264.7 
macrophages and reduced cholesterol content in 
these cells.424,425 In vivo, FPD5 reduced aortic lipid 
and cholesterol content and atherosclerotic lesions 
in Apoe knock-out C57BL/6 mice. 
Inducers of other ABCA transporters 
ABCA2 and ABCA3 
As detailed above, ABCA2 and ABCA3 are 
believed to contribute to multidrug resistance in 
cancer.171,232-239,241,242 In human K562 leukemia cells, 
it was demonstrated that the tyrosine kinase 
inhibitor (TKI) imatinib induced increased levels of 
ABCA2 mRNA and ABCA2 protein.236 Furthermore, 
the TKIs dasatinib, imatinib, and nilotinib increased 
ABCA3 mRNA levels in various cancer cell lines as 
well as in TKI-treated leukemia patients.426 The 
antimetabolite 5-fluorouracil (5-FU) induced 
expression of ABCA3 mRNA in a cholangiocarcinoma 
cell line,427 and methotrexate increased ABCA2 and 
ABCA3 mRNA in a leukemia cell line.242 Finally, the 
steroid hormone progesterone,179 the antibiotic 
sulfoxaflor,420 and the endosomal cholesterol 
transport inhibitor U18666A179 induced ABCA2/ 
Abca2 transcripts420 in Aphis gossypii420 as well as in 
ABCA2-transfected Chinese hamster ovary (CHO) 
cells and HepG2 cells179  
ABCA5 and ABCA6 
As discussed earlier, cholesterol and its 
derivatives have been shown to induce 
ABCA1/Abca1 mRNA and/or ABCA1 protein 
levels.122,205,249,252,259,262-264,268,277,278,305-315,319-328  In-
duction by cholesterol has also been demonstrated 
for Abca5 mRNA and ABCA5 protein levels in 
RAW264.7 macrophages.321 This effect relied on the 
induction of Lxra, Lxrb, and Pparg. Consequently, 
several LXR and PPAR agonists increased Abca5 
expression, including bezafibrate (PPAR-α, PPAR-β, 
and PPAR-γ; Abca5 mRNA and ABCA5 protein), 
GW3965 (LXR; Abca5 mRNA), rosiglitazone (PPAR-γ; 
Abca5 mRNA), and troglitazone (PPAR-γ; Abca5 
mRNA) in murine RAW264.7 macrophages.321 In 
addition, the HMG-CoA-reductase inhibitor 
atorvastatin increased Abca5 mRNA and ABCA5 
Free Neuropathology 2:33 (2021) Pahnke et al. 




protein levels.321 Interestingly, the ABCA1 inhibitor 
tacrolimus245 showed induction of ABCA5 mRNA in 
human brain microvascular endothelial cells.428 
The HMG-CoA-reductase inhibitors lovastatin 
and mevastatin resulted in an induction of ABCA6 
mRNA in the human endothelial cell line 
EA.hy926.429 Finally, in an Abca12 pig model of the 
rare and lethal skin disease Harlequin ichthyosis, it 
was demonstrated that treatment with the 
synthetic retinoid acitretin leads to a compensatory 
induction of Abca6 mRNA.430 
ABCA7 
Similarly to ABCA1,202 the sterane derivative 
ponasterone A increased both ABCA7 protein 
expression and ABCA7-mediated transport, mainly 
of phospholipids, but also of cholesterol to a small 
extent.202 
HMG-CoA-reductase inhibitors were described 
above to interfere with ABCA1/ 
Abca1312,318,330,343,362,411 and Abca5321 expression. In 
addition, certain compounds were also 
demonstrated to interfere with Abca7 ex-
pression.205,431 These include pravastatin205,431 and 
rosuvastatin (Figure 2).431 These agents increased 
Abca7 mRNA and ABCA7 protein levels in vitro,205,431 
whilst pravastatin had the same effects in vivo in 
murine peritoneal macrophages.431 Surprisingly, this 
increase of Abca7 mRNA and ABCA7 protein levels 
was accompanied by a downregulation of Lxra and 
upregulation of Srebp2 in vitro.431 Functionally, 
pravastatin and rosuvastatin reduced intracellular 
cholesterol content431 and induced phagocytosis in 
vitro and in vivo.431 These effects occurred in 
response to an ABCA1 downregulation by HMG-
CoA-reductase inhibitors as described 
earlier.312,321,384,432,439,429 Due to their functional 
similarity, the upregulation of ABCA7 could be a 
compensatory mechanism to counteract the loss of 
ABCA1.198 Similarly, the observed Lxra down- and 
Srebp up-regulation may be a compensatory 
mechanism to counteract the loss of intracellular 
cholesterol. 
Finally, as described for ABCA1,422 exposure of 
ABCA7-transfected BHK-21 cells to mifepristone 
increased ABCA7 protein content and ABCA7-
mediated transport of phospholipids and, to a much 
lesser extent, of cholesterol.422 
ABCA8 
ABCA8 mRNA and ABCA8 protein content were 
induced by gemcitabine in PANC-1 and CFPAC-1 
human pancreatic cancer cells.221 In rat liver, an 
induction of Abca8 was demonstrated via 
microarray analysis of cDNA when the rats were 
exposed to polyethyleneglycol-block-polylactide 
nanoparticles.433 
ABCA12 
Several LXR and PPAR agonists induced 
ABCA12/Abca12 expression, such as 22-(R)-
hydroxycholesterol (LXR),434 TO901317 (LXR),430,434 
ciglitazone (PPAR-γ),434 GI 251929X (PPAR-γ),434 
troglitazone (PPAR-γ),434 ceramide N-hexanoyl-D-
erythro-sphingosine (PPAR-δ),435 and GW610742 
(PPAR-δ).434 
Interestingly, inhibition of certain enzymes to 
prevent ceramide processing elevated intracellular 
ceramide content and subsequently ABCA12 mRNA 




pyrrolidinopropanol (D-PPPP / P4) and  
DL-threo-1-phenyl-2-de-canoylamino-3-morpholino-
1-propanol (D-DDMP)], the sphingomyelin synthase 
[tricyclo[5.2.1.02,6]decanyl)ethanedithioic acid 
(D609 xanthate)], as well as the ceramidase [D-
erythro-2-tetradecanoylamino-1-phenyl-1-propanol 
(D-MAPP) and (D-NMAPPD / B13)].435 
Downregulators 
ABCA1 
LXR and RXR pathways – intrinsic substrates 
The intrinsic metabolite asymmetric dimethyl-
arginine (ADMA) reduced Abca1 mRNA and ABCA1 
protein levels in human and murine J744 
macrophages in combination with oxLDL, resulting 
in increased intracellular cholesterol and triglyceride 
levels.392 This was accompanied by decreased efflux 
of cholesterol from these cells. The authors 
suggested a negative effect on the LXR-α pathway. 
In this regard, the LXR-α downregulator 
homocysteine significantly reduced ABCA1/Abca1 
mRNA and ABCA1 protein expression in vitro in THP-
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1 macrophages as well as in vivo in macrophages 
from Apoe knock-out C57BL/6 mice.335 The cattle 
metabolite dipeptide phenylalanine-proline 
decreased ABCA1 mRNA and ABCA1 protein levels in 
human colorectal adenocarcinoma-derived CaCo-2 
cells.436 The observed downregulation of LXRB 
mRNA could explain the negative impact on ABCA1 
expression. In vivo, the jejunal Abca1 mRNA levels 
were decreased in Wistar rats.436 
The ABCA1 substrate α-tocopherol230 reduced 
ABCA1/Abca1 mRNA levels in vitro and in vivo.231 
The same effects were observed for γ-tocopherol in 
vitro, most likely through the same mechanism. The 
authors suggested a negative impact on the LXR 
pathway due to deprived oxycholesterol derivatives 
after α-tocopherol treatment both in vitro in Hep3B 
cells and in vivo in rat liver.231 
LXR and RXR pathways - sterane and sterane-like 
natural compounds 
Cholesterol and its derivatives have extensively 
been used to induce ABCA1/Abca1 
expression122,205,249,252,259,262-264,268,277,278,305-315,319-328 
However, mid-term exposure to excess cholesterol 
decreased ABCA1 expression though a negative 
impact on Lxra, Lxrb, and Pparg expression.321 
Similar observations have been made for the sterol 
derivative dexamethasone, which also reduced 
ABCA1/Abca1 mRNA and ABCA1 protein expression 
in vitro and in vivo by downregulation of LXRA/Lxra 
mRNA and LXR-α protein levels as well as 
upregulation of Srebp2 and HMG-CoA-reductase 
gene expression (Hmgcr).437 Finally, an Abca1 mRNA 
reduction was observed in murine RAW264.7 
macrophages for the Thelenota ananas-derived 
saponin desulfated holothurin A.438 Interestingly, 
Hmgcr was downregulated after exposure to 
desulfated holothurin A, which contradicts other 
findings.437 
LXR and RXR pathways – other natural compounds 
Certain chalcone derivatives also caused 
reduced expression of ABCA1 protein.363 In addition, 
lipopolysaccharides reduced ABCA1 protein content 
in endometrial endothelial cells from C57BL/6 mice, 
which was accompanied by increased cholesterol 
levels in these cells.374 A parallel reduction in LXR-α 
protein was also observed. Finally, the carcinogenic 
agent N-nitrosodiethylamine (NDEA) demonstrated 
in vivo in Wistar albino rats a downregulation of Lxra 
and Lxrb mRNA as well as LXR-α and LXR-β protein 
levels and, subsequently, ABCA1 protein.368  
LXR and RXR pathways – synthetic compounds and 
HTS hits 
In terms of other LXR antagonists and 
downregulators, GSK2033 (Figure 2),272,330,333 
5CPPSS-50,357 and SR9243333 reduced ABCA1 mRNA 
and ABCA1 protein expression.272,330,333,357 
HMG-CoA-reductase pathways – intrinsic substrates 
and pharmacological drugs 
The peptide hormone angiotensin II reduced 
cholesterol efflux from murine peritoneal 
macrophages.439 This reduction could be reversed by 
the angiotensin II receptor antagonist losartan. The 
authors concluded that ABCA1 was not involved in 
this process, as no concurrent change in Abca1 
expression was observed.439 However, in another 
report, angiotensin II indeed demonstrated a 
reduction of ABCA1 mRNA and ABCA1 protein levels 
in human podocytes.440 The authors concluded a 
contribution of the HMG-CoA-reductase, SREBP1, 
and SREBP2.440  
Geranylgeraniol pyrophosphate (GGPP; 
Figure 2), a product of the mevalonate pathway, 
reduced ABCA1 mRNA expression in human 
macrophages, which was blocked by the prenylation 
inhibitors L836,978 and L-839,867.314 In addition, a 
reduction of ABCA1-mediated cholesterol export 
was observed, which is also true for mevalonate 
itself.318 GGPP was used as a standard ABCA1 
downregulator in certain studies.279,354,366 
As discussed above, atorvastatin,343 
fluvastatin,312 pitavastatin,318,343 and simvasta-
tin312,343 have been shown to increase ABCA1/Abca1 
mRNA levels,312,343 and to enhance ABCA1-mediated 
cholesterol efflux.318 However, atorvastatin,312,321,384 
fluvastatin,312 pitavastatin432 and simvastatin312,384 
have also been reported to reduce ABCA1/Abca1 
transcription312,321,384,432 and ABCA1-mediated 
cholesterol efflux.384,431 These observations are in 
agreement with other reports on HMG-CoA-
reductase inhibitors that downregulated 
ABCA1.312,431 In particular, lovastatin,312 mevastatin 
(compactin),412 pravastatin,431 and rosuvastatin431,441 
reduced ABCA1/Abca1 mRNA312,431 and ABCA1 
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protein431 levels. These findings are expected given 
that the loss of cholesterol by interruption of 
cholesterol synthesis leads to a compensatory 
reduction of cholesterol efflux.314384,412 The 
contradictory results relating to ABCA1 may be 
caused by the use of variable experimental 
conditions between studies, such as different cell 
lines, assay methodologies, or small-molecule-
related aspects, such as concentration, distribution, 
and protein binding. 
Finally, a similar interconnection between 
HMG-CoA and ABCA1 was drawn for the 
antineoplastic agent mitotane, which down-
regulated ABCA1 mRNA441 and increased 
intracellular cholesterol levels.333,441 However, 
mitotane in combination with LXR antagonists and 
LXR downregulators had an inverse effect on mRNA 
regulation, increasing ABCA1 expression.327 
PKC pathway - intrinsic substrates 
Interestingly, it was also demonstrated that 
long-term exposure to low concentrations 
 of 8-Br-cAMP, a standard ABCA1/Abca1 
inducer,230,249,255,266,290,292 led to decreased APOE 
secretion from human monocyte-derived macro-
phages.266 APOE secretion can be considered as a 
surrogate marker for ABCA1-mediated cholesterol 
transport. 
PPAR pathway – pharmacological drugs and 
synthetic compounds 
Regarding the important PPAR pathway, it 
must be noted that troglitazone, indicated above as 
an ABCA1 inducer,268 was also reported to 
downregulate ABCA1 transcription.321 These 
inconsistent effects may be explained partially by 
the different concentrations used (1 µM vs 10 
µM),268,321 but may also be related to cross-talk 
between the PPAR, LXR, and mevalonate pathways. 
The PPAR-γ antagonist GW9662 (Figure 2) reduced 
ABCA1 protein levels.406 
Other ABCA1 downregulators – natural compounds 
Other small-molecules have been reported to 
act as ABCA1/Abca1 downregulators, acting 
independently of the previously mentioned LXR, 
RXR, PPAR, and HMG-CoA-reductase pathways. 
Natural compounds such as α,β-unsaturated 
carbonyl derivative acrolein,442 the polyphenol 
bisphenol A,443 and the polyphenol 1,2,3,4,6 penta-
O-galloyl-β-D-glucose444 demonstrated an Abca1 
mRNA443,444 and ABCA1 protein442 downregulation in 
vitro443,442 and in vivo.444 The effect of acrolein could 
be abrogated by 3-hydroxytyrosol,442 an inducer of 
ABCA1 protein content.445 
SREBP2 has been demonstrated to be targeted 
by EGCG in high fat diet-fed transgenic SREBP+/+ 
Wistar rats, resulting in Abca1 mRNA down-
regulation, while an Abca1 mRNA upregulation 
could be observed under the same conditions in 
SREBP knock-out Wistar rats.446 
Other ABCA1 downregulators – pharmacological 
drugs 
Exposure of the human non-small cell lung 
cancer lines A549 and H358 to the antiepileptic drug 
valproate led to downregulation of ABCA1 mRNA 
and ABCA1 protein levels through a histone 
deacetylase 2-(HDAC2)-mediated mechanism. In 
parallel, the authors observed an increased 
sensitivity of these cells to cisplatin.447 
The selective estrogen receptor modulators 
raloxifene, tamoxifen, and toremifene were 
reported to reduce ABCA1 protein content in THP-1 
macrophages along with decreased cholesterol 
efflux and increased intracellular cholesterol 
levels.341 Tamoxifen and raloxifene treatment 
decreased serum HDL-cholesterol levels in mice. In 
addition, tamoxifen reduced cholesterol levels in 
serum, liver, and feces of mice after injection with 
cholesterol-loaded macrophages.341 Interestingly, 
the downregulation of ABCA1 protein content by 
these estrogen receptor modulators could not be 
demonstrated for murine liver, indicating a 
macrophage-specific effect.341 
Varenicline, a drug used in smoking cessation, 
was shown in vivo to promote aortic atherosclerotic 
lesions in Apoe knock-out C57BL/6 mice.417,448 The 
authors demonstrated that intracellular lipid 
content in peritoneal macrophages was increased, 
and a decreased ABCA1 protein expression was 
confirmed in vitro in RAW264.7 macrophages. 
Finally, the antineoplastic agent gefitinib reduced 
ABCA1 protein content in various non-small cell lung 
cancer cell lines.400 
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Other ABCA1 downregulators – synthetic 
compounds 
The plasticizer dibutyl phthalate389 and the 
PI3K/AKT inhibitor LY294002421 reduced ABCA1 
mRNA389 and ABCA1 protein389,421 expression and 
increased cellular cholesterol and lipid levels389 in 
human389 and murine421 macrophages. 
The sphingosine kinase 1 and 2 inhibitor 4-{[4-
(4-chlorophenyl)-2-thiazolyl]amino}phenol was 
demonstrated to downregulate ABCA1 protein 
expression in murine primary macrophages, which 
was dependent on the sphingosine kinase 2 as well 
as the sphingosine-1-phosphate receptor.306 This 
ABCA1 protein downregulation was accompanied by 
a reduced cholesterol efflux. 
The acyl coenzyme A cholesteryl acyl 
transferase (ACAT) inhibitor ATR-101 reduced 
ABCA1 mRNA levels and induced an increase in 
intracellular cholesterol content in H295R cells.251 
The authors suggested that this was caused by 
inhibition of ABCA1 but provided no clear proof of 
direct inhibition of ABCA1. Therefore, this 
compound was classified as a downregulator. 
Other ABCA transporters 
ABCA2 and ABCA3 
Compared to ABCA1, knowledge relating to 
downregulators of the other ABCA transporters is 
very limited. As discussed above, human leukemia 
cells exposed to imatinib displayed increased ABCA2 
mRNA and ABCA2 protein expression.236 Celecoxib 
abrogated this effect.236 A similar observation was 
reported for ABCA3, where the anti-inflammatory 
drug indomethacin and the ABCA1 inhibitor 
sirolimus245 (Figure 2) downregulated ABCA3 mRNA 
in various cancer cell lines.426,449,450 This treatment 
also resulted in a sensitization of these cell lines 
toward the TKIs dasatinib, imatinib, and nilotinib 
when treated with indomethacin.426 
Other compounds were also reported to 
downregulate ABCA3/Abca3 including the flavonoid 
genistein,451 lipopolysaccharides452 – already 
demonstrated above as ABCA1 protein down-
regulators374 – and the translocator protein ligand 
PK11195.453 The effect of lipopolysaccharides could 
be abrogated by ascorbic acid (vitamin C). 
ABCA5–ABCA9 
Interestingly, the ABCA8 inhibitor222 and ABCA1 
protein inducer253 digoxin downregulated Abca5 
and Abca7–9 in murine liver.454 The HMG-CoA-
reductase inhibitors lovastatin and mevastatin 
downregulated ABCA6 mRNA in human umbilical 
vein endothelial cells.429 The cholesterol derivative 
25-hydroxycholesterol, which was introduced above 
as an ABCA1 mRNA inducer,327 showed the opposite 
effect on ABCA7 mRNA.324 This finding is in 
agreement with a report stating that excess 
cholesterol reduced ABCA7 protein content in both 
human and murine fibroblasts.205 
Stabilizers of ABCA transporters 
Stabilizers are compounds that promote 
functional activity of ABC transporters through 
increasing their presence at the site of action (e.g., 
the cell membrane) either without interfering with 
mRNA or protein levels, or in addition to these 
effects. The categorization is difficult, as the 
necessary information regarding many modulators 
of ABCA transporters is lacking and the underlying 
mode of modulation cannot be precisely identified. 
In this section, we consider only those modulators 
which predominantly interfere with ABCA1 
trafficking, with relatively minor or no additional 
modes of action/modulation. Stabilizers are of 
particular interest, as they may represent a novel 
generation of functional ABC transporter activators, 
expanding treatment options for several diseases, 
particularly AD. 
ABCA1 
Probucol and cyclosporine A were demon-
strated above to decrease ABCA1 turnover and 
increasing ABCA1 protein content at the cell 
membrane.246,275 Arakawa et al. demonstrated that 
the probucol metabolites spiroquinone and 
diphenoquinone did not inhibit ABCA1-mediated 
transport like their parent compound but rather 
increased the fraction of functional ABCA1 in the cell 
membrane.275 This stabilization led to increased 
cholesterol and phospholipid efflux. Both effects 
were observed at very low nanomolar 
concentrations,275 while Abca1 mRNA remained 
stable.275 Strikingly, spiroquinone and 
diphenoquinone decreased vascular lipid deposits in 
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vivo in cholesterol-fed rabbits,275 which may be of 
relevance for AD and potentially other 
neurodegenerative diseases. 
A similar mode of stabilization, albeit with less 
potency and no in vivo confirmation, has been 
observed for the flavonoid wogonin,254 the olive oil-
derived compound erythrodiol,395 and certain thiol 
proteinase inhibitors, in particular N-acetyl-Leu-Leu-
norleucinal and leupeptin.316,386 Finally, the ABCA1 
mRNA and ABCA1 protein inducer testosterone was 
demonstrated to promote ABCA1 trafficking to the 
cell membrane.357  
Other ABCA transporters 
The cystic fibrosis transmembrane con-
ductance regulator (CFTR; ABCC7) correctors C13,455 
C14,455 C17,455 genistein,456 and ivacaftor 
(Figure 2)456 were demonstrated to rescue ABCA3 
mutants by increasing total ABCA3 mutant protein 
levels,455 promoting subcellular targeting of ABCA3 
into vesicular bodies,455 and improving lipid 
transport function of ABCA3.456 Furthermore, the 
correctors lumacaftor (VX-809; Figure 2), C3, and C4, 
and C18 increased the presence of ABCA4 at the cell 
membrane in ABCA4-overexpressing HEK293 cells, 
indicating promotion of ABCA4 trafficking to the 
plasma membrane.457,458 Promotion of trafficking 
has already been demonstrated for other ABC 
transporters, such as ABCC123,24 and ABCC7.459 
Hence, this mechanism represents a new potential 
therapeutic option for ABCA transporter-related AD. 
As proposed for ABCC7,460 the authors suggested a 
direct binding of the correctors to the ABCA4 
protein,457 which has not yet been proven. 
In an Abca12 pig model of Harlequin ichthyosis, 
acitretin (Figure 2) treatment resulted in a 
redistribution of ABCA12 in the skin compared to 
wild-type pigs, and thus, a higher survival rate.430 
Destabilizers of ABCA transporters 
Natural compounds 
In contrast to compounds that promote 
trafficking of functional ABCA1 to the plasma 
membrane, other compounds that have the 
opposite effect have been named ‘destablizers’. So 
far, only agents targeting ABCA1 are known. The 
lactone antibiotic brefeldin A (Figure 2) interfered 
with ABCA1 cell-surface localization, recycling, and 
intracellular trafficking.387,461-463 These effects were 
at least in part dependent on the interaction with 
brefeldin 1-inhibited guanine nucleotide exchange 
protein (BIG1).461 This interference reduced the 
functional fraction of ABCA1 and, consequently, 
ABCA1-mediated cholesterol and phospholipid 
transport.255 Similar observations have been made 
for the polyether-antibiotics monensin, which 
reduced ABCA1 turnover and trapped it inside endo- 
and lysosomes. Subsequently, monensin reduced 
the functional presence of ABCA1 at the cell 
surface,464 lowered cholesterol efflux,463 and 
increased intracellular cholesterol content.463,464 The 
same was demonstrated for nigericin, another 
polyether-antibiotic, which increased intracellular 
cholesterol concentration,463 and inhibited ABCA1-
mediated cholesterol efflux from RAW264.7 
macrophages.385 Inhibition of intracellular organelle 
transport as suggested for brefeldin A387,461-463 and 
monensin463,464 likely applies to nigericin as 
well.463,465 In addition, the endoplasmic reticulum 
stress promotor, tunicamycin, also reduced ABCA1 
protein levels.360,466 This ‘downregulation’ is most 
likely mediated though stress-induced impaired 
ABCA1 trafficking and/or increased ABCA1 
degradation.466 However, in terms of selective 
targeting of ABCA1 in particular, or ABCA 
transporters in general, these agents are less 
suitable as in vivo agents and serve better as in vitro 
controls. 
The palmitic acid derivative 2-bromopalmitate 
(Figure 2) inhibited trafficking of ABCA1 to the 
plasma membrane and reduced ABCA1-mediated 
cholesterol efflux.273,467 However, the observed 
effect that ABCA1 did not translocate to the cell 
membrane in HEK293/ABCA1 cells467 has not been 
demonstrated in BHK-21/ABCA1 cells.273 
Pharmacological drugs 
Interestingly, the experimental anticancer drug 
serdemetan (JNJ-26854165) was demonstrated to 
induce Abca1 mRNA levels but reduce ABCA1-
mediated cholesterol efflux.468 The Abca1 mRNA 
induction was due to induction of Lxra and Lxrb. The 
Abca1 mRNA increase was also reflected at the 
protein level, which increased within 48 hours of 
exposure to serdemetan before a sudden decrease 
occurred. The authors also showed that ABCA1 
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turnover and degradation were increased. Thus, 
serdemetan can be considered a destabilizer. 
Synthetic compounds 
Cycloheximide was frequently used to 
interrupt intracellular trafficking of vesicles, 
including ABCA1 containing endo- and 
lysosomes.387,464,468 
As mentioned earlier, ABCA1 is stabilized by N-
acetyl-Leu-Leu-norleucinal.316,386 This stabilization 
could be abrogated by the protein kinase C inhibitor 
Gö6976, which affected not only ABCA1 protein 
content, but also cholesterol and phospholipid 
transport.386 
PART II: PIPELINE DEVELOPMENT TO 
GAIN NOVEL DIAGNOSTICS AND 
THERAPEUTICS 
In silico methodologies to predict novel lead 
structures 
Rational drug design is the innovative process 
of identifying pharmaceutically relevant drug 
candidates. It is based on the information obtained 
in association with the drug target, e.g., ABC 
transporters. In the following section, we will discuss 
computational approaches for in silico operations 
that help to identify novel lead molecules for 
potential diagnostic and therapeutic application. 
Structure-based drug design 
The development of computational 
methodologies for structure-based drug design to 
understand the relationship between transporter 
sequence/structure and function depends on the 
availability of structural as well as biological 
information. Recent advances in experimental 
approaches for structure determination have 
facilitated high-quality depictions of the structures 
of a growing number of ABC transporters in different 
conformational states.469 These experimental 
approaches include in particular X-ray crystallo-
graphy and cryo-electron microscopy (cryo-EM). 
Recently, the cryo-EM structures of human 
ABCA1470 and human ABCA4471-473 with resolutions 
of 4.1 Å and 3.3–3.6 Å, respectively, were reported. 
In addition, a cryo-EM structure of human ABCA7 
has been announced474 on bioRxiv (biorxiv.org), 
which was, however, not published to this date (PDB 
ID: 7KQC). Nevertheless, a homology model of 
ABCA7 has been recently developed.475 Figure 4 
shows the structures of ABCA1, ABCA4, and ABCA7 
as determined by cryo-EM as well as homology 
modelling. 
Considering the available structural 
knowledge, a ‘common’ ABCA transporter possesses 
a very long amino acid sequence (>2000 amino 
acids) and consists of two membrane-spanning 
domains (MSD1 and MSD2) each composed of six 
transmembrane helices (TM1–6 and TM7–12). 
These MSDs are followed by a cytoplasmic region 
comprising a nucleotide-binding domain (NBD1 and 
NBD2) and a small regulatory (R1 and R2) domain, 
which have been proposed to stabilize the 
interaction between NBD1 and NBD2470,473 and were 
found to strongly interact with each another in the 
absence of ATP.471,472 
ABCA transporters are ‘type II transporters’ in 
which the MSDs indeed form a tunnel for substrate 
translocation from the cytosol to the lumen, 
however, represent separate entities without 
swapping/twisting of the MSDs, as this is the case 
with classical ‘type I transporters’ like ABCB1.476 
Most TMs are completely exposed to the 
hydrophobic environment of the membrane, which 
could promote the attraction and binding of fat-
soluble cholesterol as well as phospholipids before 
guidance to and through the substrate translocation 
tunnel, and which hosts several cholesterol and 
phospholipid binding sites.470-474 
A unique feature amongst ABCA transporters in 
comparison to other ABC transporters is the 
existence of two large extracellular domains (ECD1 
and ECD2). These domains together form a channel 
embedded in hydrophobic amino acids470-472 and are 
believed to facilitate intermediate storage of 
cholesterol470 and phospholipids. They have also 
been suggested as the primary binding site of 
APOA1,471,477 as indicated by the latest data on 
ABCA4.471 A large gap exists between the ECDs and 
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Figure 4. Available structures of ABCA transporters: the cryo-EM structures of human ABCA1470 (very left; PDB ID 5XJY) and ABCA4 [left 
(PDB ID 7LKP, middle (PDB ID 7E7I), and right (PDB ID 7M1Q)]471-473 as well as the homology model developed for human ABCA7 (very 
right).475 All three transporters are typical ABCA transporters with three crucial structural parts: two nucleotide-binding domains (NBDs; 
intracellular), two membrane-spanning domains [MSDs (2 x 6 transmembrane helices TMs); inter-membrane space], and two large 
extracellular domains (ECDs; extracellular). 
 
MSDs, pointing to strong conformational changes 
that are required for ABCA transporter function.470 
Another common feature amongst ABCA 
transporters are four intracellular and extracellular 
helices (IH1–4 and EH1–4), which are believed to 
provide the necessary flexibility for interaction 
between the MSDs and NBDs in the substrate 
translocation process,478 and were suggested to 
enable proper folding and function of these 
transporters.471 
Of important note is that ABCA1 and ABCA4 
share sequential and structural similarities with the 
ABCG family, in particular with ABCG5/ABCG8,470 
which is the model type II transporter.478 This 
similarity suggests an evolutionary relevance 
amongst various ABC transporter subfamilies. More 
importantly, conserved sequential and structural 
similarities also support the translation of 
knowledge gained on other ABC transporter 
subfamilies to ABCA transporters.470,472 This is of 
particular interest when novel lead structures for 
new pharmacological targets, in this case under-
studied ABC transporters,18 are focused,6,18 and 
specific binding sites located within the MSDs or 
NBDs are targeted. 
Based on the sequence information of ABC 
transporters within the same family, homology-
modeling techniques are the preferred choice for 
structure determination and binding site elucidation 
if these subtypes do not yield X-ray or cryo-EM 
structures. This methodology is of particular 
relevance for closely related homologs with high 
medical relevance,198 such as ABCA7 (similarity 
A1/A7: 54%; similarity A4/A7: 49%).200 The 
generated homology models can be refined further 
by molecular dynamics simulation, in which the 
transporter movement (‘trajectory’) is simulated to 
potentially unravel relevant transporter 
conformations. Very recently, potential ABCA1 drug 
binding sites have been proposed by this 
methodology,479 and an ABCA7 homology model has 
been developed for molecular docking 
experiments.475 
Molecular docking is a very popular method for 
predicting binding orientations or poses of small-
molecules within the transporter. Most often, the 
docking programs account for full conformational 
flexibility of ligands within the binding site, treating 
the protein as a rigid body. Binding site identification 
is an important prerequisite in the structure-based 
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drug design implementation. In terms of ABC 
transporters, the search for binding hot spots and 
cavities on the entire volume of the protein (e.g., 
through blind docking) is necessary due to the 
general lack of information on binding sites of ABC 
transporters. 
Recently, in search of highly effective 
modulators addressing ABCG2-mediated MDR, 
derivatives of quinazolines were synthesized and 
biologically assessed using a Hoechst 33342 
accumulation assay.480 By utilizing the cryo-EM 
structure of ABCG2,481 molecular docking studies 
were performed using a fragment-based 
approach.482 This approach was used to gain insights 
into the molecular determinants involved in the 
formation of the transporter-substrate complex.480 
Based on the docking studies, the putative binding 
site of the ABCG2 substrate, Hoechst 33342, and its 
interaction with the amino acids in the binding 
pocket was proposed.480 The predicted binding pose 
was rationalized based on the mutagenesis data 
reported in the literature483-487 and further 
confirmed with kinetic studies to determine the 
mode of inhibition.480 This subsequent structure-
based approach led to the discovery of highly potent 
pyrimidine-based ABCG2 inhibitors,488,489 specifically 
by identifying a novel binding pocket of this 
transporter.488 In terms of ABCA transporters, 
molecular docking experiments with the newly 
derived ABCA7 homology model applying a set of 
diverse pan-ABC transporter inhibitors revealed a 
putative common ‘multitarget binding site’ 
identified within the transmembrane domains of 
ABCA7. It must be noted that the nucleotide binding 
domains are the most highly conserved regions 
amongst all ABC transporters, and hence, may also 
represent a(nother) multitarget binding site for 
certain drugs. However, the vast majority of data 
reported in the past hint to the transmembrane 
domains as the actual venue of bioactivity in terms 
of ABC transporter modulation.472 
These results as described above475,480,488,489 
give this methodology a high relevance in the drug 
development process in terms of novel lead 
molecules in general, and provide the basis for 
rationally designed structure-guided approaches for 
the identification of modulators of ABCA 
transporters in particular, as recently demonstrated 
for ABCA7.475 
Ligand-based drug design 
Similarity search 
The analysis of structure-activity relationships 
using ligand-based approaches is an essential 
component of medicinal chemistry and 
pharmacology of ABC transporters. This becomes 
evident as X-ray or cryo-EM structures of most ABC 
transporter subtypes are lacking to serve as suitable 
templates with sufficient similarity for generating 
homology models. Ligand-based approaches 
establish a correlation between the molecular 
structure of a small-molecule and the triggered 
biological response of the target. The chemical 
representation of the molecules is often expressed 
using descriptors, which are attributes that conserve 
the physicochemical information of the molecule. 
These descriptors refer to generic properties such as 
LogP, molecular weight, polar surface area, 
rotatable bonds, or molar refractivity. Alternatively, 
structural representations of the molecules can 
form fingerprints that portray existent molecular 
features of the molecule in a binary code. These 
fingerprints are, for example, path-like,490 or 
circular-based,491,492 such as MACCS or ECFP4, 
respectively. Utilizing these representations of 
molecules, similarity-driven virtual screenings can 
be applied. Here, molecules are extracted from a 
virtual library of millions or billions of compounds 
compared to the bioactive template molecule(s) 
according to the similarity principle. The abstract 
representation of molecules enables clustering of 
compounds, which is a methodology to categorize a 
diverse set of molecules. Moreover, these abstract 
representations can be used in different machine 
learning (artificial intelligence) approaches. 
Pharmacophore modelling 
Another common approach is pharmacophore 
modelling, which analyzes a number of ligands with 
a common mechanism of action. The model is the 
ensemble of common chemical features that are 
required to ensure the molecular interaction of the 
ligands with the target, such as hydrogen bond 
donors and acceptors as well as aromatic and 
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hydrophobic centers. The pharmacophore models 
are generated by extracting common molecular 
features through flexible alignment of the active 
biomolecules.493,494 This can be achieved by 
generating all possible conformations of the ligand 
and aligning them to determine the essential 
chemical features and molecular orientation to 
construct the pharmacophore model. The 
conformational flexibility of the ligands representing 
the chemical features is the key factor in the 
pharmacophore model generation. 
Pattern analysis 
In addition to these classical computational 
approaches, similarity search and pharmacophore 
modelling, a pattern analysis approach (‘C@PA’ = 
computer-aided pattern analysis’) has been 
reported recently.18,19,495 Pattern analysis extracts 
both basic scaffolds and the statistical distribution of 
substructural elements amongst the template 
ligands. It works similarly to non-physicochemical 
properties-related fingerprints and conserves 
substructural features as they are present in the 
molecules. Pattern analysis has specifically been 
derived for the development of novel potent 
multitarget ABC transporter inhibitors. The basic 
operations were the categorization of bioactive 
molecules according to their inhibitory power 
against specific ABC transporters and their 
classification according to their selectivity profile. 
The respective classes can statistically be analyzed 
for both their basic scaffolds and/or their 
substructural composition to extract the desired 
pharmacological profile and target preferences. The 
generated model focused multitargeting of ABC 
transporters, and resulted in a biological hit rate of 
21.7%.19 Adaption of the model (‘C@PA_1.2’) 
through additional non-statistical and exploratory 
measures increased the biological hit rate to 40%,18 
and an additional extension of the model enabled 
the discovery of the ‘outer multitarget modulator 
landscape’, which represented weak multitarget 
bioactivities (>10 µM) supporting the discovery of a 
larger number of multitarget agents.495 The hit rates 
are impressive considering that this approach takes 
several targets with individual ‘ligand preferences’ 
into account. Furthermore, as several ABC 
transporters of distinct subfamilies were considered 
(ABCB1, ABCC1, ABCG2), the resultant multitarget 
agents open up the possibility to explore under-
studied ABC transporters,18 in particular ABCA 
transporters in terms of AD.6,14 
Combined approaches 
Apart from the individual use of these 
methodologies, combined approaches may lead to 
improved hit rates and better prediction capabilities 
with respect to bioactivity of small-molecules. This 
has in particular been demonstrated for a combined 
virtual screening approach using similarity search 
and pharmacophore modelling for the discovery of 
novel ABCC1 inhibitors.493 Also, certain pattern 
analysis approaches have used a data set derived 
from a similarity search and pharmacophore 
modelling approach, and hence, can also be 
considered a combined computational 
approach.18,495 
In vitro methodologies to assess novel lead 
structures 
The previous sections have already outlined 
the diverse testing systems that have been used to 
assess the modulatory effects of effectors toward 
ABCA transporters. The following section will 
highlight the ABCA transporter-expressing host 
systems and the related assays that can be 
implemented into the pipeline for the assessment of 
novel lead molecules as potential ABCA transporter 
diagnostics or therapeutics. 
Host system of ABCA transporters 
The transporter host system (ABCA transporter 
carrying unit) can be categorized into (i) living-cell-
based or (ii) membrane preparation-/vesicle-based 
(including isolated and reconstituted proteins). The 
vast majority of biological investigations used living 
cells. Here, two different living cell-based 
transporter host systems can be differentiated: (i) 
native/induced/selected cells and (ii) transfected 
cells. 
Native ABCA transporters-expressing living cells 
Native/induced/selected cells naturally ex-
press the respective ABCA transporter or have been 
exposed to a ‘standard’ inducer, for example, the 
Free Neuropathology 2:33 (2021) Pahnke et al. 




ABCA1 inducers 22-(R)-hydroxy-cholesterol,122,205,249, 
252,259,262-264,268,277,278,305-315 TO901317,205,245,250,252,259, 
260,262,264,271,272,279,280,282,308,310,317,319,322,324,326,328-345 or 8-
Br-cAMP,230,249,255,266,290,292 and overexpress the 
respective transporter in response (e.g., ABCA1). 
Most commonly, human or murine cells have been 
used. Table 4 summarizes the cell lines used to 
assess the ABCA transporter modulators discussed 
in the previous sections. It must be noted that the 
addressed pathways regulate also the 
overexpression of other ABC transporters. In terms 
of the studies of ABCA1, the co-expression (i.e., co-
up-regulation and co-downregulation) of other 
members, such as ABCG1, has frequently been 
observed.160,320,335,364,366,402,410,418,421,448 
In terms of ABCA1, most studies have been 
conducted with human THP1,231,245,249,256,268, 
272,275,292,308,310,312-316,321,328,335,338,339,341,342,360,363,364,366,37
7,384,388-397 murine J774.A1,252,254,255,259,265,271,278, 
289-292,384,392,393 or murine RAW264.7 macro-
phages.230,249,312,313,321,336,339,342,352,360,365,367,369,375,376,381
,385,399,402,404,406,408,410,416-419,421,424,425,438,442,448 In the 
set-up of a drug development pipeline, these cell 
lines are the backbone of the in vitro assessment of 
potential candidates. 
Regarding other ABCA transporters, the 
situation is much more complicated due to the lack 
of cell lines that naturally (and almost exclusively) 
express the respective ABCA transporter. 
Consequently, these ABCA transporters are much 
less studied and well-established. However, 
transfected cell lines are of great help to study one 
particular transporter instead of using native cell 
lines that may co-express several members. 
ABCA transporters-transfected living cells 
In terms of ABCA1, cell lines transfected with 
human ABCA1 have often been used, e.g., human 
embryonic kidney (HEK) cells (HEK293/ABCA1)171, 
201,202,249,260,267,270,275,329,352,386,464,467,498,499 and baby 
hamster kidney (BHK) cells (BHK-21/ABCA1).230, 
245,273,292,422 These transporter host systems have also 
been used to study other transporters, ABCA2,498,500 
ABCA3,235,241,498 ABCA4,133-136,201,457,458,501,502 
ABCA5,503 ABCA7,201,202,386,422,498 ABCA8,10 ABCA12,498 
and ABCA13.48 
Transfected cells often express lower levels of 
the introduced transporter than native cell lines, 
which is a problem if the host cell lines (e.g., HEK or 
BHK-21) naturally express other ABC transporters as 
well. However, these transporter host systems are 
suitable to confirm results, and might be the only 
possibility to address ABCA transporters other than 
ABCA1. 
Isolated ABCA transport proteins 
Finally, apart from intact cells, vesicles of 
enriched or purified/reconstituted ABCA 
transporters have also been used to assess 
transporter function. Compared with living-cell 
based assays, this kind of host system is rarely 
represented in the literature regarding ABCA 
transporters.133-139,201,499-502,504-506 Specifically ATPase 
assays are popular to assess functional ABC 
transporter modulation.23,24,507-510 While transport 
protein purification and reconstitution in vesicles or 
nano discs requires advanced engineering, and is 
expensive and resource-consuming, membrane 
preparations of transporters, in particular for 
ATPase assays, are much more feasible. However, 
this method has been used somewhat scarcely for 
ABCA transporter function assessment.133-135,137-
139,201,499-502,504-506 
Functional assessment of ABCA transporters 
Two groups of tracers have been established in 
terms of ABCA transporter function: (i) radiolabeled 
substrates,250,272,305,306,338,339,354,364,366,393,395,404,419,511,51
2,136,222,230,245,249,253,255,259,260,262,264,265,267-270,273,276,278,289-




Radiolabeled tracers of ABCA transport function 
In terms of radiolabeled substrates, cholesterol 
is by far the most frequently used genuineABCA1 
substrate,230,245,249,255,260,264,265,267-270,272,273,276,278,289-292,
305,306,313,315,318,329,338,339,354,366,367,381,384,385,393-395,404,408,41
9,464,467,499,512 followed by phospholipid(-
components).249,255,267,269,273,311,464,467,514 However, 
other substrates have also been used. These 
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Table 4. Non-exhaustive list of native ABCA transporters-expressing cell lines that have been established in the assessment of small-molecule modula-
tors of ABCA transporters. 
    
Cell type Cell line name Origin References 
    
ABCA1    
colorectal adenocarcinoma cells CaCo-2 human 262,264,308,314,342,436 






















adipocytes 3T3 L-1 mouse 255 












astrocytoma CCFSTTG1 human 423 
peripheral blood mononuclear cells PBMC human 411 
breast cancer cells MCF-7 human 331 







aortic endothelial cells  HAEC human 263,269 
endometrial endothelial cells  mouse 374 
umbilical vein endothelial cells  HUVEC human 269,364,442,496 
epithelial cells BEAS-B2 human 322 
lung epithelial cells  mouse 311 
pigment epithelial cells  human 257 
mouse mammalian epithelial cells MMEC mouse 350 
aortic smooth muscle cells SMC human 269 
vascular smooth muscle cells VSMC unspecified origin 332 















granulosa cells  rat 443 
















insulinoma cells INS-1 rat 405 
keratinocytes  human 282 
embryonic kidney cells  human 312 

















liver cells L02 human 406 
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Cell type Cell line name Origin References 











































multiple myeloma MM human 468 
neuroblastoma Neuro-2a murine 359 
neutrophils primary human 339 
nephron cells A6 frog 258 
periodontal ligament stem cells  human 325 
pheochromocytoma  PC12 rat 280 
podocytes  human 440 
retina cells ARPE-19 human 354 
oral squamous cell carcinoma cells CAL27 human 371 




   
ABCA2    
hepatoma HepG2 rat 179 




   
ABCA3    
cholangiocarcinoma M214-5FUR human 427 
lung epithelial cells MLE-12 mouse 452 
hepatoma HepG2 rat 451 
























   
ABCA5    
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substrates include mostly molecules with sterane 
scaffold, such as β-sitosterol (ABCA1)262 and 
estradiol-β-glucuronide (ABCA8).222 Moreover, lipid-
like substrates have attracted attention, like 
sphingosine-1-phosphate (ABCA1),229,496 α-
tocopherol (ABCA1),230 and ATRA (ABCA4).136 
Notably, radiolabeled substrates are very effective 
in terms of accurate tracing of protein function, as 
these molecules are not changed in their molecular 
integrity in contrast to fluorescence 
probes.171,201,238,251,252,254,256,258,261,271,282,308,319,321,330,332
,335,342,360,379,389,390,392,397,402,406,455,456,468,514-518 On the 
downside, conducting these experiments is 
constrained to regulatory requirements and 
requires extensive staff training as well as expensive 
safety measures and laboratory equipment. 
Fluorescent tracers of ABCA transport function 
Regarding fluorescent derivatives of cho-
lesterol and phospholipids, two major types can be 
differentiated: (i) 7-nitro-2,1,3-benzooxadiazole 
(NBD) derivatives201,251,252,254,256,258,261,308,335,342,360,379, 
389,390,392,394,397,402,406,408,468 and (ii) 4,4-difluoro-4-
bora-3a,4a-diaza-s-indacene (BODIPY) 
derivatives.271,282,319,321,330,332,455,456,515-517 Other 
fluorophore-labeled dyes have been reported, too, 
including the sterane analog dansyl-
estramustine,171,238,518 and propargyl choline, which 
is processed in vitro into propargylated 
phospholipids.514 
In addition to the stated fluorescent tracers of 
ABCA transport function, several other derivatives 
of other substrates can be proposed. For example, 
N-3-oxododecanoyl-L-homoserine lactone (3OC12-
HSL) was suggested as ABCA1 substrate, but final 
proof was missing.519 Thus, it may be a suitable 
candidate for validation in a new set-up in vitro 
assay for ABCA1 (and potentially other ABCA 
transporters). Other examples of potential probes 
are fluorescenct dyes that stand in association with 
cellular cholesterol and phospholipid distribution 
and ABCA1-mediated cholesterol and phospholipid 
transport.516 These include, for example, β-BODIPY 
FL C5-HPC, β-BODIPY FL C12-HPC, BODIPY TR 
ceramide, and Red/Green BODIPY PC-A2, amongst 
many others.520-522 
 
Fluorescenct dyes are well-established tracers 
of ABC transporter function,18,19,23,24,284,480, 
488,489,493,507,523-525 and the knowledge that has 
accumulated regarding the well-studied ABC 
transporters ABCB1, ABCC1, and ABCG2 can be 
transferred to ABCA transporters as well. However, 
the added fluorophore changes the molecular 
composition of the tracing molecules. This alteration 
inheres the potential risk of changing affinities and 
even the binding site(s) of these molecules, 
undermining functional-kinetic analyses regarding 
binding site determination and elucidation of the 
mode of action. Nevertheless, fluorescence probes 
are – if used and established correctly – extremely 
reliable, and can be used without regulatory 
restrictions and necessity of special equipment, 
except for microplate readers and/or flow 
cytometers. 
Colorimetric determination of ABCA transport 
function – ATPase assays 
As mentioned above, ATPase assays have also 
been used to functionally analyze ABCA transporter 
function, in particular for ABCA1,201,499,505,506 
ABCA2,500 ABCA3139,504 ABCA4,133-135,137,138,201,501,502 
and ABCA7,201 although this methodology has been 
used somewhat rarely compared to other functional 
approaches. ATPase assays are based on the 
principle that the active transport of any substrate 
of ABC transporters consumes energy. This energy is 
derived from the cleavage of ATP to ADP and Pi, and 
can be detected by different methodologies.23,24, 
507-510,526 Table 5 highlights known ATPase 
modulators of ABCA transporters and the associated 
literature reports. 
ATPase assays have been and still are popular 
in terms of functional ABC transporter modulation in 
general.23,24,507-510 Strikingly, the NBDs of ABC 
transporters are – in contrast to the various binding 
sites identified within the transmembrane domains 
of ABC transporters475 – highly conserved. This 
conservation enables targeting of ABCA NBDs by 
known ATPase modulators of other ABC 
transporters. Therefore, ABCA transporter function 
can be detected by methodologies that have already 
been established for other ABC 
transporters.23,24,507-510,526 This transfer of knowledge 
Free Neuropathology 2:33 (2021) Pahnke et al. 




will be of great use to confirm obtained results from 
other functional ABCA transporter analyses. 
Colorimetric determination of ABCA transport 
function – other detection methodologies 
As a final note, it must be mentioned that other 
colorimetric analyses were also used to quantify the 
ABCA transporter-mediated function, specifically for 
transport of cholesterol or choline- 
containing lipids, using commercially available assay 
kits.202,205,246,251,268,272,275,329-332,334,336,354,365,366,369,372,374-
376,386-389,392,405,406,416,418,421,422,424,425,441,511 However, 
these methodologies require time-consuming 
extraction processes of the lipids, and hence, are 
less suitable to track the function of ABCA 
transporters in real-time and to determine kinetic 
aspects of their cholesterol and lipid transport. 
In rare instances, the extraction of lipid 
components was accomplished after incubation 
with a radioactive marker.246 While this is a valid 
methodology to accurately determine lipid 
components within cells, it increases workload and 
attracts regulatory constraints. 
Gas-liquid chromatography has also been used 
in some reports.353,355 An extraction-free staining of 
cholesterol inside of cells was also demonstrated 
(filipin III251,331,333,341,358 or Oil Red O staining 330, 
332,364,366,369,375,388,389,392,393,399,402,410,417,421,425,448). 
However, these systems are not suitable to 





Table 5. Summary of known ATPase modulators of ABCA transporters. 
    
Transporter Modulator Mode of modulation References 
ABCA1 ceramide (30 mol–%) 
cholesterol (30 mol–%) 
phosphatidylcholine (30 mol–%) 
phosphatidylethanolamine (30 mol–%) 
phosphatidylinositol (30 mol–%) 
phosphatidylserine (30 mol–%) 















ABCA2 methyl-β-cyclodextrin (u.c.a) activation 500 
ABCA4 amiodarone (20–75 µM) 
2-tert-butylanthraquinone (20–50 µM) 
ceramide (30 mol–%) 
cholesterol (30 mol–%) 
dehydroabietylacetate (10–50 µM) 
digitonin (10–180 µM) 
N-ethylmaleimide (NEM; 1000 μM) 
reduced glutathione (GSH; 1000 μM) 
β-ionone (50–100 µM) 
phosphatidylethanolamine (30 mol–%) 
phosphatidylglycerol (30 mol–%) 
phosphtidylinositol (30 mol–%)  
11-cis-retinal (5–100 µM) 
13-cis-retinal (5–100 µM) 
ATRA (5–100 µM; EC50 = 10 µM) 
all-trans-retinoic acid (20–100 µM) 
all-trans-retinol (20–100 µM) 





































ABCA7 ceramide (30 mol–%) 
cholesterol (30 mol–%) 
phosphatidylcholine (30 mol–%) 
phosphatidylethanolamine (30 mol–%) 












a u.c. = unspecified concentration 
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Quantification of ABCA transporter regulation 
Besides qPCR and western blotting, ABCA 
transporter expression was reported in several 
studies using fluorimetric assays. This was 
accomplished with either (i) green fluorescent 
protein-(GFP)- tagged/labelled ABCA 
transporters235,241,261,275,386,422,464,504 or (ii) luciferase 
promotor-(LUC)-transfected271,309,319,352,367,379,381,405, 
406,419,436,447 ABCA transporter cells in luciferase 
reporter gene assays. 
In vivo assessment of clinical candidates 
In vivo models play a key role in drug discovery. 
Although in vitro and cellular models are less 
expensive and less time consuming, in vivo models 
are needed to test ABCA modulators under 
physiological conditions. Safety, toxicity, and 
efficacy of a drug candidate must be tested in an in 
vivo model as a last step before transferring it to 
clinical evaluation. However, these models also have 
disadvantages. Animal studies are time consuming 
and require advanced personnel training and 
resources for maintaining the animals. In addition, 
although they are closer to humans than in vitro 
models, there are considerable physiological 
differences between species with respect to drug 
absorption, metabolism, and excretion, which may 
impede translatability. Furthermore, the use of 
animals in research has its ethical concerns. Thus, in 
recent years, research has been directed to reduce 
animal use and increase animal welfare. 
In vivo models have previously been used to 
study the role of ABCA transporters in physiology 
and disease as described above. Thus, there are 
already available animal models for testing of ABCA 
modulators for the most prominent subtypes 
(Table 6). As stated above, these models represent 
the last step before clinical evaluation of potential 
small-molecule therapeutics in humans. Thus, after 
in silico identification and in vitro assessment, these 
in vivo models are the third column in the 
development of novel ABCA transporter diagnostics 
and therapeutics. In the following section, different 
in vivo models will be described in more detail. 
Knock-out mouse models 
A genetic knock-out mouse model is an animal 
model in which one or more genes of interest have 
been deactivated or removed by means of gene 
targeting. Knock-out animals allow for direct 
investigation of the effect of a specific gene in an 
organism, as the loss of gene activity often causes 
phenotypic changes uncovering the function and 
biological mechanism of the targeted gene.535 
Knock-out mice have become one of the most useful 
scientific tools to analyze the human genome and its 
potential roles in many diseases.535 Thus, knock-out 
animals are currently essential experimental tools 
for the investigation of genetic disorders and the 
evaluation of novel drugs.536 Furthermore, the 
current knowledge on genome editing using the 
CRISPR/Cas9 system makes generation of knock-out 
lines considerably faster than with the use of 
embryonic stem cells. To no surprise, this method 
has quickly become the most powerful tool for 
generating genetic models.537  
Knock-out animal models are designed with 
two variables in mind: (i) where and (ii) when is the 
gene of interest deactivated. The simplest and most 
common approach is a constitutive, ubiquitous 
knock-out, i.e., the product protein is absent 
permanently in all cells of an organism. To overcome 
limitations of this broad approach, more refined 
models have been developed. These conditional 
models use Cre-Lox recombination to target a gene 
either in specific cell populations, at specific time 
points, or a combination of both. Here, the target 
gene is modified by inserting two loxP sites. The 
flanked gene segment can then be excised by the 
Cre recombinase. Cre activity, i.e., gene knock-out, 
can be limited to certain cell populations by 
appropriate promotor choice and/or linked to a 
tamoxifen-responsive element to control the exact 
time point at which the knock-out is induced. 
Until now, several Abca animal knock-out 
models have been described, which are summarized 
in Table 6. These models are mainly mouse lines, 
except for ABCA13 (monkey).534 These animal 
models have contributed fundamentally to  
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Table 6. Animal models to study the functional and pathological role of ABCA transporters. 
     
Transporter Type Species Phenotype References 
ABCA1 knock-out mouse 
 
reduced cholesterol and plasma phospholipid levels  
decreased brain APOE levels  





overexpression mouse increased lipidation of APOE 127 
ABCA2 knock-out mouse reduced body weight, limb tremor, reduced sphingomyelin https://www.jax.org/ 
strain/033139  
54,527 






early macrophage predominant alveolitis which peaked at 8 




ABCA4 knock-out mouse abnormal phospholipid composition, delayed dark adaptation 531,532 


























mouse reduced plasma HDL 
 
533 
adenoviral overexpression mouse increased plasma HDL and cholesterol 533 
ABCA12 - - not described https://www.jax.org/ 
strain/033630  
ABCA13 knock-out mouse 
 
monkey 
deficits of prepulse inhibition 
 






identifying the role of ABCA transporters in 
physiological conditions as well as in disease 
pathogenesis. In addition, these models can be used 
for novel drug testing, as they provide information 
about target specificity. If a drug is 100% specific for 
a transporter, knock-out of this transporter should 
completely abolish the drug’s effects observed in 
naïve animals. However, gene knock-outs often 
have phenotypical effects per se that need to be 
taken into account when evaluating drug effects.  
RNAi models 
The use of RNA interference (RNAi) is an 
alternative to knock-out models. This technique is 
based on post-transcriptional silencing of the 
targeted gene using siRNA molecules that are 
designed to bind to the target mRNA.538 This process 
will deactivate the mRNA using the cell’s own 
defense mechanism against pathogens. In contrast 
to standard knock-out models, this silencing is 
temporary as the siRNA molecule will be degraded 
but the gene transcription continues.527  
To avoid this temporal limitation, short-hairpin 
RNA (shRNA) has been developed. This method is 
based on the use of vectors that incorporate into the 
cell DNA and encode for shRNA. After transcription, 
these vectors are processed into siRNA. These 
shRNAs are continuously transcribed, increasing 
reproducibility of results.539 
Overexpression models 
Similar to knock-out models, overexpression 
models can be used to investigate the function of a 
gene by evaluating the resultant phenotype. In 
addition, overexpression models have long been 
used for modeling diseases such as AD540 or PD.541  
In the investigation of ABCA transporters, these 
models can resemble the effect of chronic activation 
of the transporters and may help to identify its 
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physiological functions by evaluating the pathways 
upregulated in comparison to control animals.127  
Humanized ABC transporter mouse models 
Before it can be translated into clinical practice, 
each novel drug candidate must be tested in an in 
vivo model. However, the translational value of the 
animal model largely depends on whether the 
disease pathway under investigation is conserved 
between the two species. Therefore, replacing the 
original (e.g., murine) gene by the respective human 
gene likely improves the animal model, and thus, is 
beneficial for evaluating a novel drug’s efficacy and 
specificity in clinical practice.542 With this approach, 
mice can be used as tools for pre-clinical screening 
and efficacy evaluation of new drugs, given their 
improved ability to predict human responses to 
treatments. 
Our group has previously established a 
humanized ABCC1 mouse model,543 and an ABCA7 
model is under characterization. Here, we 
generated knock-in mouse models producing a 
chimeric protein that is completely human except 
for one amino acid.543 In addition, as this gene was 
flanked by loxP sites, this humanized model can be 
knocked out in specific cell populations and at a 
specific age.543 Models such as these represent the 
future of pre-clinical drug candidate evaluation. 
In addition, Dallas et al. successfully generated 
a humanized ABCG2 mouse model.544 However, 
other models, such as humanized ABCB1 mice, were 
not successful despite multiple attempts.545  
Disease models 
In addition, all the models described above can 
also be used to study the role of a gene for the 
pathophysiology of specific diseases. For example, 
Abca knock-out models have been crossed with 
transgenic mice in order to study their potential role 
in AD.54,123,131,161-163,527 These studies have elucidated 
potential disease mechanisms involving ABCA 
transporters that cannot be studied in patients. 
Moreover, once a drug is developed and its 
specificity is proven, disease models enable 
evaluation of the role of that specific transporter in 
the pathophysiology of the disease. At the same 
time, these results may be the first step to evaluate 
the potential of novel transporter modulators as 
therapy for the respective disease. 
Imaging techniques 
Lastly, in vivo imaging can be used for the 
development of new drugs. On the one hand, 
labeling drug candidates with radioactive isotopes 
can give information about the drug distribution, 
drug target, and drug metabolism in vivo. In 
addition, it can also show whether a drug is able to 
cross specific natural barriers, such as the BBB. In 
vivo imaging can help to select candidates that 
appear successful or to discard drugs that seem 
likely to fail.546 
On the other hand, drug candidates can also be 
used to develop new radiotracers (e.g., PET tracers) 
targeting ABCA transporters that could then be used 
in clinical diagnostics. Radiotracers would facilitate 
the study of the specific gene and/or its product 
protein in human patients in vivo and in a 
longitudinal fashion, enabling a much better 
understanding of the role of ABCA transporters in 
human (patho)physiology.547 In this regard, knock-
out animals can be used as negative controls for the 
development of new ABCA radiotracers to evaluate 
the specificity of the radiotracer.548 Furthermore, 
these very same radiotracers can be used in animal 
disease models, enabling longitudinal studies and 
reducing the number of animals required.549-551  
CONCLUDING REMARKS: WHERE DO 
WE GO FROM HERE? 
Several in vivo studies demonstrated that 
modulators of ABCA transporters, in particular 
ABCA1, have systemic effects.231,249,250,253,271,275,289,293, 
297,330,335,344,350,361,362,366,368-370,376,378,383,410,415,417-419,425,43
1,436,448 However, the vast majority of these 
modulators were regulators,231,250,253,271,297, 
330,335,344,350,361,362,366,368-370,376,378,383,410,415,417-419,425,431,43
6,448 specifically inducers,250,253,271,297,330,344, 
361,362,366,368-370,376,378,383,410,415,418,419,425,431 and only 
very few interactors demonstrated in vivo 
effects.249,289,293 Mostly emphasizing athero-
sclerosis,249,275,289,366,369, 370,378,410,417-419,425,431,448 these 
regulators were able to demonstrate that cellular 
and plasma lipid content249,271,275,289,330,366,369, 
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378,419,425,431 as well as atherosclerotic plaque 
formation275,289,366,369,370,410, 417-419,425,448 could be 
changed compared to controls (enhanced or 
reduced) after treatment with the respective drug. 
Only very few in vivo approaches targeted for 
AD.293,297,344,383 
Taking the challenge of CNS penetration of 
these drugs into account, drugs active in 
atherosclerosis models could generally be suggested 
to also have certain therapeutic relevance regarding 
AD. Nevertheless, so far, none of these drugs has 
made it into clinical evaluation in humans. The 
underlying cause can be pinned to the fact that the 
principal mechanism by which ABCA transporters 
contribute to AD is still unknown. While a rationale 
can be found in atherosclerosis (efflux of cellular 
lipid to APOE and HDL resulting in lower lipid burden 
in the vascular system), the translation of this 
rationale to AD can only be achieved to a very 
limited extent. Several questions need addressing in 
future evaluations: (i) what is the general function of 
ABCA transporters in the brain to ameliorate (or 
exacerbate) AD in patients; (ii) when does this 
development start; and (iii) at which stage of 
development can a pharmacological intervention 
with ABCA transporter modulators lead to a positive 
therapeutic effect? 
In this regard, more in vitro tests are needed 
with new lead structures that are rigorously 
assessed for their particular mechanism of action – 
to study vice versa the mechanism of action of ABCA 
transporters in general. One possibility to gain novel 
lead structures is the screening of huge analog 
compound libraries. However, the number of 
existing compounds is limited, and blind in vitro 
testing is resource-consuming, especially regarding 
time and funds. Computational methodologies may 
help to generate novel lead structures based on the 
knowledge of existing modulators of ABCA 
transporters. This has led to new lead molecules in 
the past.18,19,493,495 Particularly the knowledge on 
ABCA1 and ABCA8 inhibitors and substrates is of 
interest, because these compounds inherit the 
molecular-structural information that is critical for 
direct binding to these transporters. Considering the 
newly developed pattern analysis methodology, 
C@PA,18,19,495 the scaffolds and substructural 
composition of this set of molecules may reveal the 
critical necessities for direct interaction with ABCA 
transporters. C@PA is therefore of high relevance 
because it was specifically developed to gain 
multitargeting pan-ABC transporter 
modulators18,19,495 – molecules that particularly 
interact with different ABC transporters of different 
subfamilies. Assuming that a conserved multitarget 
binding site exists as proposed earlier,6,14,475 
multitargeting may be the key to explore under-
studied ABC transporters in general and ABCA 
transporters in particular.6,14,18,19 Several thousands 
of these molecules have already been 
predicted,18,19,493,495 and the predictions were in part 
biologically confirmed.18,19,493,495 Additionally, 
selected pan-ABC transporter inhibitors were 
analyzed in molecular docking studies, which 
revealed the potential existence of the multitarget 
binding site.475 Hence, combining the existent 
knowledge of ABCA transporter modulators with 
(sub)structural elements of these pan-ABC 
transporter modulators and powerful 
computational approaches (e.g., molecular docking 
or molecular dynamics simulations) could ultimately 
lead to the successful exploration of ABCA 
transporters in general, as well as ABCA1 and ABCA7 
in particular.28,95,103-112 
Several drugs and drug-like compounds have 
already been demonstrated to be pan-ABC 
transporter modulators interacting also with ABCA 
transporters. These drugs and drug-like compounds 
are, for example, cyclosporine A (9 targets of 4 
subfamilies: ABCA1,245 ABCB1,20 ABCB4,552 
ABCB11,553 ABCC1–2,24,554 ABCC10,26 and ABCG1–
2555,556), glibenclamide (8 targets of 4 subfamilies: 
ABCA1,270 ABCB11,553 ABCC1,24 ABCC5,557 ABCC7–
9,558-560 and ABCG2554), imatinib (6 targets of 4 
subfamilies: ABCA3,426 ABCB1,561 ABCB11,553 
ABCC1,561 ABCC10,561 and ABCG2561), probenecid (8 
targets of 2 subfamilies: ABCA8,222 ABCC1–6,24,26,562-
564 ABCC10565), verapamil (9 targets of 4 subfamilies: 
ABCA8,222 ABCB1,20 ABCB4–5,552,566 ABCB11,567 
ABCC1,24 ABCC4,568 ABCC10,565 and ABCG2554), and 
verlukast (11 targets of 4 subfamilies: ABCA8,222 
ABCB4,552 ABCB11,553 ABCC1–5,24,554,557,564,569 
ABCC10–11,26,570 ABCG2554). In silico analyses with 
verapamil and verlukast supported the notion of 
addressing the multitarget binding site in ABCA7.475 
Taking their structural peculiarities in a pattern-
based rational drug design approach into account 
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may yield novel lead structures for functional in vitro 
studies of ABCA transporters. This may ultimately 
result in the development of innovative AD 
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